Non-human animals comprising genetically modified endogenous IGHA loci and methods of making same
By introducing the human IgA1 heavy chain constant region gene into non-human animals and treating them with immunostimulants, the gene editing limitations of existing IgA nephropathy models have been overcome, and a transgenic animal model capable of simulating the pathological process of human IgA1 has been established for studying the pathogenesis of IgA nephropathy and evaluating therapeutic drugs.
Patent Information
- Application Number
- CN202380032311.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-03-21
- Filing Date
- 2023-08-31
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-08-31
AI Technical Summary
Existing animal models of IgA nephropathy have limitations in gene editing technology and limited renal histological changes when studying the pathogenesis of IgAN, making it difficult to effectively simulate the pathological process of human IgA1.
By introducing the human IgA1 heavy chain constant region gene into the endogenous Igha locus of non-human animals using the CRISPR/Cas system, and treating the animals with an immunostimulant, a transgenic non-human animal model showing an increase in galactose-deficient IgA protein was prepared.
A non-human animal model capable of simulating the pathological process of human IgA1 was established, showing clinical signs associated with IgA nephropathy, such as elevated IgA1, glomerular deposition, and histological changes, which is suitable for evaluating the efficacy of therapeutic drugs.
Smart Images

Figure CN118984875A_ABST
Abstract
Description
Technical Field
[0001] The present invention generally relates to transgenic non-human animals that can be used to study diseases associated with IgA deposition. More specifically, the present invention relates to transgenic non-human animals comprising genetically modified endogenous IgA loci, as well as methods for preparing the transgenic non-human animals or uses of the transgenic non-human animals. Background Art
[0002] IgA is the main pathological antibody isotype of IgA nephropathy (IgAN), with three forms, monotype IgA, secretory IgA and IgA-containing complexes. Compared with healthy volunteers, IgA concentrations in the serum of IgAN subjects are elevated (Wang M, Lv J, Zhang X et al., Kidney Int Rep 2020; 5: 165-172). IgAN is characterized by the presence of IgA dominant or co-dominant immune deposits in the glomeruli and elevated galactose-deficient IgA1 (or "Gd-IgA1"). A 'multiple hits' hypothesis has been proposed to explain the pathogenesis of IgAN, and galactose-deficient IgA1 (Gd-IgA1) is defined as the first heavy hit. Gd-IgA1 is believed to form nephritogenic high molecular immune complexes to induce renal injury (Novak J, Barratt J, Julian BA et al., Semin Nephrol 2018; 38: 461-476). Only human primates and humans have O-glycosylated IgA1 subclasses. Therefore, humanized IgA1 animals may be helpful in studying the pathogenesis of IgAN. A fully human IgA1 knock-in (α1KI) mouse model was generated and backcrossed with human CD89 Tg mice to develop an IgAN-like disease model (Duchez S, Amin R, Cogne N et al., Proc Natl Acad Sci USA 2010; 107: 3064-3069; Berthelot L, Papista C, Maciel TT et al., The Journal of experimental medicine 2012; 209: 793-806). However, due to the limitations of gene editing technology, human IgA1 replaced the mouse IgM heavy chain in this α1KI mouse (Wehbi B, Oblet C, Boyer F et al., J Am Soc Nephrol 2019;30:1238-1249). The coexistence of human IgA1 and mouse IgA, but not IgM, in α1KI mice may interfere with the study of the pathogenesis of IgAN. Some classic IgAN models generally show limited renal histological changes with or without genetic manipulation.
[0003] Therefore, new animal models of IgAN are needed to understand the mechanisms behind this disease and to develop therapeutic approaches. Summary of the invention
[0004] In one aspect, the present disclosure provides a method for preparing a genetically modified non-human animal. Specifically, the method comprises: (i) modifying the genome of the non-human animal to incorporate nucleotides containing a heterologous gene into its endogenous Igha locus, wherein the heterologous gene encodes a human IgA1 heavy chain constant region or a fragment thereof; and (ii) treating the non-human animal produced in step (i) with a formulation containing an immunostimulant.
[0005] In some embodiments, step (i) includes introducing nucleotides comprising the heterologous gene into the pluripotent cells of the non-human animal, thereby obtaining non-human animal pluripotent cells comprising the heterologous gene, and using the non-human animal pluripotent cells comprising the heterologous gene to prepare non-human animals. In some embodiments, the nucleotides comprising the heterologous gene are introduced into the pluripotent cells of the non-human animal by using the CRISPR / Cas system. In some embodiments, the CRISPR / Cas system comprises Cas9 protein and guide RNA, and the guide RNA targets the guide RNA target sequence within the endogenous Igha locus. In some embodiments, the pluripotent cells are embryonic stem (ES) cells. In some embodiments, a segment or all of the endogenous non-human animal Igha gene at the endogenous non-human animal Igha locus has been deleted and replaced with the nucleotides comprising the heterologous gene. In some embodiments, the non-human animal does not express an endogenous non-human IgA heavy chain constant region.
[0006] In some embodiments, the nucleic acid comprising the heterologous gene is operably linked to an endogenous regulatory element (eg, a promoter, enhancer, silencer, etc.) of the non-human animal.
[0007] In some embodiments, the nucleotides comprising the heterologous gene are genomic fragments of human IGHA1 genes. In some embodiments, the heterologous gene comprises both human IGHA1 coding sequences and non-coding sequences. In some embodiments, the non-human animal produces chimeric IgA1, the heavy chain of which comprises a non-human animal variable region and a human constant region or a fragment thereof. In some embodiments, the human IgA1 heavy chain constant region of the non-human animal comprises an O-glycosylated hinge region. In some embodiments, the heterologous gene is a human IGHA1 gene encoding a human IgA1 heavy chain constant region or a fragment thereof.
[0008] In some embodiments, the formulation comprises an immunostimulant and an antigen. In some embodiments, the formulation consists of an immunostimulant. In some embodiments, the immunostimulant is selected from the group consisting of: an aluminum adjuvant, an emulsion adjuvant, a biological adjuvant, and a saponin.
[0009] In some embodiments, the aluminum adjuvant is selected from the group consisting of aluminum hydroxide (Al(OH)3), aluminum phosphate, aluminum hydroxyphosphate, and amorphous aluminum hydroxyphosphate sulfate (AAHS). In some embodiments, the aluminum adjuvant is aluminum hydroxide.
[0010] In some embodiments, the emulsion adjuvant is an oil-in-water emulsion adjuvant or a water-in-oil emulsion adjuvant. In some embodiments, the water-in-oil emulsion adjuvant is selected from the group consisting of complete Freund's adjuvant (CFA), incomplete Freund's adjuvant, MF59 and AS03.
[0011] In some embodiments, the biological adjuvant is selected from the group consisting of: lipopolysaccharide or a derivative thereof, a toll-like receptor (TLR) agonist (e.g., TLR4 ligand, TLR7 ligand, TLR8 ligand, TLR9 ligand), an immunostimulatory oligonucleotide (e.g., DNA or dsRNA containing CpG), a cytokine (e.g., IL-12), an interferon, an endotoxin, and a lipid (e.g., lipid A or its analogs). In some embodiments, the biological adjuvant is lipopolysaccharide or a derivative thereof.
[0012] In some embodiments, the antigen comprises a rhamnose source. In some embodiments, the rhamnose source is Lactobacillus casei cell wall extract (LCWE).
[0013] In some embodiments, in step (ii), the non-human animal produced in step (i) is treated with a formulation comprising LCWE emulsified with CFA.
[0014] In some embodiments, in step (ii), the formulation is injected intraperitoneally into the non-human animal. In some embodiments, the formulation is injected intraperitoneally into the non-human animal as a continuous low dose. In some embodiments, the formulation is injected intraperitoneally into the non-human animal at a dose of less than 1 μg LCWE and / or less than 5 μL CFA per gram of the non-human animal produced in step (i).
[0015] In some embodiments, the formulation is administered to the non-human animal for at least one month. In some embodiments, the formulation is administered to the non-human animal for at least three months. In some embodiments, the formulation is administered to the non-human animal produced in step (i) at intervals of three times per week in the first two weeks and once per week in the next two weeks for a period of one month. In some embodiments, the formulation is administered to the non-human animal produced in step (i) at intervals of once every two weeks for a period of three months.
[0016] In some embodiments, the non-human animal is a rodent, a mammal, or a non-human primate. In some embodiments, the rodent is a mouse or a rat.
[0017] In another aspect, the present disclosure provides a non-human animal produced by the methods described herein. In some embodiments, the non-human animal provided herein exhibits an increased level of galactose-deficient IgA protein. In some embodiments, the non-human animal exhibits an increased level of galactose-deficient IgA protein in serum or intestinal mucus.
[0018] In some embodiments, a segment or the entirety of an endogenous non-human animal Igha gene at the endogenous non-human animal Igha locus has been deleted and replaced with nucleotides comprising the heterologous gene. In some embodiments, the non-human animal does not express an endogenous non-human IgA heavy chain constant region.
[0019] In some embodiments, the nucleotides comprising the heterologous gene are operably linked to the endogenous regulatory elements (e.g., promoters, enhancers, silencers, etc.) of the non-human animal. In some embodiments, the nucleotides comprising the heterologous gene are genomic fragments of the human IGHA1 gene. In some embodiments, the heterologous gene comprises both the human IGHA1 coding sequence and the non-coding sequence. In some embodiments, the non-human animal produces a chimeric IgA1, the heavy chain of which comprises a non-human animal variable region and a human constant region or a fragment thereof. In some embodiments, the human IgA heavy chain constant region of the non-human animal comprises an O-glycosylated hinge region. In some embodiments, the heterologous gene is a human IGHA1 gene encoding a human IgA1 heavy chain constant region or a fragment thereof.
[0020] In some embodiments, the non-human animal is a rodent, a mammal, or a non-human primate. In some embodiments, the rodent is a mouse or a rat.
[0021] In another aspect, the present disclosure provides for use of the non-human animals described herein as animal models for diseases associated with IgA deposition.
[0022] In some embodiments, the disease associated with IgA deposition is selected from the group consisting of: IgA nephropathy, dermatitis herpetiformis, Henlein-Schuh purpura (also known as IgA vasculitis), Kawasaki disease, purpuric nephritis, IgA vasculitis renal injury, IgA rheumatoid factor positive rheumatoid arthritis, IgA-mediated anti-GBM disease or IgA-mediated ANCA-associated vasculitis. In some embodiments, the disease associated with IgA deposition is IgA nephropathy, IgA vasculitis or Kawasaki disease.
[0023] In another aspect, the present disclosure provides a method for evaluating the efficacy of a candidate drug for treating or preventing a disease associated with IgA deposition, the method comprising: providing a non-human animal as described herein; administering the candidate drug to the non-human animal; and evaluating whether the candidate drug inhibits one or more symptoms of the disease compared to a non-human animal control not administered the candidate drug.
[0024] In another aspect, the present disclosure provides a method for identifying a candidate drug for treating or preventing a disease associated with IgA deposition, the method comprising: providing a non-human animal as described herein; administering a candidate drug to the non-human animal; and evaluating whether the candidate drug inhibits one or more symptoms of the disease compared to a non-human animal control not administered the candidate drug. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] The following drawings form part of this specification and are included to further demonstrate certain aspects of the present disclosure. The present disclosure may be better understood by referring to one or more of these drawings in conjunction with the detailed description of specific embodiments presented herein.
[0026] Figure 1 shows the IGHA1 + / + Mouse development. (A) Schematic representation of the human IGHA1, mouse Igha, and humanized IGHA1 genomic loci, not to scale. The mouse Igha gene (including the entire coding region) was deleted and replaced by the human IGHA1 gene. (B) In the presence of diluted WT, IGHA1 + / - and IGHA1 + / + Mouse IgA and human IgA were examined by immunoblotting in mouse and human sera. (CD) WT, IGHA1 + / - and IGHA1 + / + Immunohistochemical staining of mouse IgA and human IgA1 in mouse Peyer patches and small intestine. (E) BCR seq shows that immunoglobulin subtypes are expressed in IGHA1. + / + IGHA1 is expressed in the terminal ileum of WT and PP mice.+ / + The J gene usage frequency of hIgA1 in mice and mouse IgA in WT mice. (G) The CDR3 sequence length distribution of hIgA1 or IgA in three IGHA1 + / + and WT mice. mIgA, mouse IgA; hIgA1, human IgA1; Homo, human.
[0027] Figure 2 Demonstrated that pathogen exposure promotes hIgA1 production in multiple organs. (A) Western blot of 1:1000 diluted GF, SPF, and CV-reared IgA1 + / + Human IgA1 was detected in mouse serum and human serum diluted 1:5000. (B) Serum hIgA1 and Gd-IgA1 levels in the above three groups at 4 months of age. (C) RT-qPCR determination of IgA1 in GF, SPF and CV-fed mice + / + mRNA expression of IGHA1 in SP, ILN, PP, and MLN of mice. Relative gene expression was normalized by GAPDH. (DE) hIgA1 in SI lamina propria + Representative confocal images and mean fluorescence intensity (AU) of cells. Scale bar = 50 um.
[0028] Figure 3 Demonstrated antigen-induced IGHA1 in LCWE + / + The levels of serum Gd-IgA1 and hIgA1-containing complexes increased in mice. (A) Towards 2-month-old IgHA1 + / + Mice were intraperitoneally administered LCWE plus CFA or PBS, and observation was extended to 8 months of age. (B) IGHA1 + / + Mice produce LCWE-specific hIgA1 and Gd-IgA1. (CE) LCWE- and PBS-induced IGHA1 + / + Levels of serum hIgA1, Gd-IgA1, and hIgA1-containing complexes in mice. (F) Serum hIgA was purified and stained with Coomassie protein or immunoimaged with anti-hIgA1 antibodies. (GH) LCWE and PBS-induced IgA1 + / + In mice, the average amount of GalNAc per HR was equal, while the Gal / GalNAc ratio decreased with increasing antigenic stimulation.
[0029] Figure 4 We show that TD and TI pathways are responsible for enhancing mucosal-derived Gd-IgA1. (A) IGHA1 induced in LCWE + / +The concentrations of hIgA1 and Gd-IgA1 were high in the small intestinal mucus of mice. (B) Immunofluorescence staining of hIgA1 and Gd-IgA1 showed enhanced LCWE-induced IGHA1 + / + Gd-IgA1 in the lamina propria of the small intestine of mice + Plasma cells. Scale bar = 50 um. (CF) mRNA expression of BAFF, APRIL, TGFβ and iNOS was increased by LCWE stimulation. Relative gene expression was normalized by GAPDH.
[0030] Figure 5 Gd-IgA1 induces severe complement activation and pathological damage in the kidney. (A) Immunostaining of CD31, human IgA1, and C3, and Gd-IgA1 shows that IGHA1 is induced in LCWE. + / + In mice, human IgA1 and C3 are deposited in the kidney mesangial region. Scale bar = 50 um. (BC) Semi-quantitative levels of hIgA1 and C3 deposition in the mesangial region. (D) Representative micrographs of PAS and Masson staining showing LCWE-induced IGHA1 + / + Mesangial expansion, hypercellularity, and tubulointerstitial fibrosis in mice. Scale bar = 50 um. Electron micrographs of glomeruli in each group show that IGHA1 + / + Electron-dense deposits in the mesangial region in mouse. Scale bar = 1 um.
[0031] Figure 6 The human IGHA1 gene was shown to be + / + (A) PCR analysis using primers covering the 5' arm or 3' arm of the knock-in IGHA1 gene and specific primers for the mouse Igha gene was performed to detect WT, IGHA1 + / - and IGHA1 + / + IGHA1 gene in mice. (B) Expression of mouse IgA and human IgA1 genes in WT, IGHA1 + / - and IGHA1 + / + Expression in mice. (C) WT, IGHA1 + / - and IGHA1 + / + Serum mouse IgA and human IgA1 levels in mice. (DE) Mouse IgA and human IgA levels in WT, IGHA1, and IGHA1 were measured by RT-qPCR. + / - and IGHA1 + / +mRNA expression in spleen and small intestine of mice. Relative gene expression was normalized to that of GAPDH. (FI) Anti-mouse IgA from WT, IGHA1 and AF647 were labeled with B220 conjugated with APC / Cy7, anti-mouse IgA conjugated with FITC and anti-human IgA1 conjugated with AF647. + / - and IGHA1 + / + Cells from the spleen, small intestine, bone marrow, and lymph nodes of mice showing IgA + B220 + The frequency of B cell counts.
[0032] Figure 7 IGHA1 + / + Mice can produce a variety of immunoglobulins like WT mice. (A) IGHA1 + / + The frequency of V gene usage of hIgA1 in mice and IgA in WT mice. (B) Venn diagram showing the frequency of V gene usage of hIgA1 in mice and IgA in WT mice. + / + Cluster analysis of IGH in WT and WT mice. (C) IGHA1 + / + Cluster distribution diagram of the top 100 IGH clusters in WT and WT mice. The percentages represent the proportions of the top 100 IGH clusters in the entire detected IGH.
[0033] Figure 8 IGHA1 raised in GF, SPF and CV at 4 months old is shown + / + Mouse serum contains hIgA1 complex ( Figure 8 A), IgM and IgG( Figure 8 B) level.
[0034] Fig. 9 Demonstrated decreased IGHA1 by LCWE stimulation + / + The weight of mice ( Fig. 9 A), and sequentially LCWE and PBS-induced IGHA1 + / + Serum IgM and IgG levels in mice ( Fig. 9 B).
[0035] Fig.10 An example of a representative extracted ion chromatogram for the analysis of hIgA1 hinge region O-glycopeptides is shown.
[0036] Fig.11 H&E staining of the heart vessels and thoracic and abdominal aorta of PBS and LCWE-induced mice is shown ( Fig.11 A), and the urine albumin / creatinine ratio, serum creatinine, and serum urea nitrogen ( Fig.11 B).
[0037] Fig.12Shown are the levels of immunoglobulins in the sera of 5-month-old mice injected intraperitoneally with CFA.
[0038] Fig.13 Shown are immunofluorescence of cryosections of kidneys from 7.5-month-old mice injected intraperitoneally with CFA.
[0039] Fig.14 Shown are the results of PAS pathological staining of the kidneys of 4-month-old mice and 5-month-old mice injected intraperitoneally with CFA.
[0040] Fig.15 Shown are the results of PAS pathological staining of the kidneys of 6-month-old mice and 7.5-month-old mice injected intraperitoneally with CFA.
[0041] Fig.16 Shown is a comparison of SCr and ACR levels in 5-month-old mice and 7.5-month-old mice injected intraperitoneally with CFA.
[0042] Fig.17 Shown are the levels of immunoglobulins in the sera of 4-month-old mice and 7-month-old mice treated with different administration routes.
[0043] Fig.18 Shown are immunofluorescence of kidney cryosections from 7-month-old mice treated with different routes of administration.
[0044] Fig.19 Shown are the results of PAS pathological staining of kidneys of 7-month-old mice treated with different administration routes.
[0045] Fig. 20 WT, IGHA1 + / - (i.e., KIWT) and IGHA1 + / + Immunohistochemical staining of mouse IgA and human IgA1 in spleens of (ie, KIKI) mice.
[0046] Fig.21 AD shows the semiquantitative scoring of immunofluorescence images and PAS-stained micrographs by professional pathologists. (A) Human IgA1 intensity; (B) Mouse IgA intensity; (C) C3 intensity; (D) Mesangial cell excess score.
[0047] Fig.22A -B shows the serum human IgA levels of each group treated with PBS, saponin, Al(OH)3, LPS, IFA, CFA and LCWE-CFA, respectively.
[0048] Fig.23A-B shows the serum human IgA-mouse IgG complex levels of each group treated with PBS, saponin, Al(OH)3, LPS, IFA, CFA and LCWE-CFA, respectively.
[0049] Fig.24A -B shows the urine albumin-creatinine ratio (ACR) of each group treated with PBS, saponin, Al(OH)3, LPS, IFA, CFA and LCWE-CFA, respectively.
[0050] Fig.25 Deposition of human IgA (hIgA) and C3 in each group treated with PBS, saponin, Al(OH)3, LPS, IFA, CFA, and LCWE-CFA, respectively, and PAS staining, as measured by immunofluorescence and PAS pathological staining assays of the kidneys, are shown.
[0051] Fig.26A -C shows the semi-quantitative scoring of immunofluorescence images and PAS-stained micrographs by professional pathologists. (A) Mouse IgM intensity; (B) Human IgA intensity; (C) C3 deposition intensity. DETAILED DESCRIPTION
[0052] The specific features of the invention (including method steps) are mentioned in the above summary of the invention and in the following specific embodiments and claims and in the drawings. It should be understood that the disclosure of the invention in this specification includes all possible combinations of such specific features. For example, where specific features are disclosed in the context of a specific aspect or embodiment of the invention or a specific claim, the features may also be used in combination with other specific aspects and embodiments of the invention and / or in the context of other specific aspects and embodiments of the invention to the extent possible, and may be used generally in the present invention.
[0053] Where reference is made herein to a method comprising two or more defined steps, the defined steps may be performed in any order or simultaneously (unless the context excludes this possibility), and the method may include one or more other steps performed before any defined step, between two defined steps, or after all defined steps (unless the context excludes this possibility).
[0054] All publications, patents, and patent applications cited in this specification are incorporated herein by reference, just as if each individual publication, patent, or patent application was specifically and individually designated as incorporated by reference and is incorporated herein by reference, so as to disclose and describe the methods and / or materials in conjunction with the cited publications. Reference to any publication is for its disclosure prior to the filing date, and is not to be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the publication dates provided may be different from the actual publication dates, which may need to be separately confirmed.
[0055] In general, unless otherwise expressly indicated, the terms used herein should conform to their understood meanings in the art. Explicit definitions of certain terms are provided herein and below; in specific cases throughout the specification, the meanings of these and other terms are clear to those skilled in the art from the context. Additional definitions of the following terms and other terms are set forth throughout the specification.
[0056] I. Definitions
[0057] It should be understood that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pluripotent cell" is a reference to one or more pluripotent cells and includes equivalents thereof known to those skilled in the art, and so forth.
[0058] As used herein, the term "comprising" and its grammatical equivalents are used herein to mean that other components, ingredients, steps, etc. are optionally present. For example, a method "comprising" (or "which includes") steps A, B, and C may consist of steps A, B, and C (i.e., contain only these steps), or may contain not only steps A, B, and C, but also one or more other steps.
[0059] The term "or" used in the claims is used to mean "and / or" unless explicitly indicated to refer to only alternatives or the alternatives are mutually exclusive, although the present disclosure supports a definition referring to only alternatives and "and / or." As used herein, "another" may mean at least a second or more.
[0060] As used herein, the term "locus" refers to the specific location of a gene, a DNA sequence, a polypeptide coding sequence, or a position on the chromosome of the genome of an organism. A known locus may contain known gene information, such as one or more polymorphic marker sites. For example, an "Igha locus" may refer to an Igha gene, an Igha DNA sequence, a specific position of an immunoglobulin heavy chain constant region α-coding sequence, or an Igha position on the chromosome of the genome of an organism, and the position has been identified as the position where such a sequence resides. An "Igha locus" may include regulatory elements of an Igha gene, including, for example, an enhancer, a promoter, a 5' and / or 3' untranslated region (UTR) or a combination thereof.
[0061] As used herein, the term "gene" refers to a DNA sequence in a chromosome that encodes a product (e.g., an RNA product and / or a polypeptide product). In some embodiments, a gene includes a coding sequence (i.e., a sequence encoding a specific product). In some embodiments, a gene may also include a non-coding sequence. In some specific embodiments, a gene may include both a coding (e.g., exon) sequence and a non-coding (e.g., intron) sequence. In some embodiments, a gene may include one or more regulatory sequences (e.g., promoters, enhancers, etc.) and / or intron sequences, for example, one or more aspects of gene expression (e.g., cell type-specific expression, inducible expression, etc.) may be controlled or affected. For the sake of clarity, it should be noted that the term "gene" used in this application generally refers to a portion of a nucleic acid encoding a polypeptide; the term may optionally encompass a regulatory sequence, which will be clear to a person of ordinary skill in the art in the context. This definition is not intended to exclude the application of the term "gene" to non-protein coding expression units, but to clarify that, in most cases, the term used in this document refers to a nucleic acid encoding a polypeptide.
[0062] As used herein, a "coding sequence" or sequence that "encodes" a selected polypeptide is a nucleic acid molecule that is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide, for example when placed under the control of appropriate regulatory sequences (or "control elements") in vivo. The boundaries of the coding sequence are generally determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. The coding sequence may include, but is not limited to, cDNA from a virus, prokaryotic or eukaryotic mRNA, genomic DNA sequences from a virus or prokaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence may be located at the 3' end of the coding sequence.
[0063] The term "operably linked" refers to an arrangement of elements in which the components so described are configured to perform their usual functions. In the case of a promoter, a promoter operably linked to a coding sequence will direct the expression of the coding sequence. A promoter or other control element need not be linked to a coding sequence as long as the promoter or other control element functions to direct its expression. For example, an intermediate untranslated but still transcribed sequence may be present between a promoter sequence and a coding sequence, and the promoter sequence may still be considered to be "operably linked" to a coding sequence.
[0064] As used herein, the term "IgA" refers to one of the antibody (immunoglobulin) isotypes, which is also called immunoglobulin alpha. As used herein, IgA is also called "IgA antibody" or "IgA-type antibody". In serum, IgA exists mainly in the form of monomeric IgA (serological IgA), and IgA1 is the main component. When secreted into the mucosa, IgA exists in the form of polymeric IgA (secretory IgA or SIgA), which is a dimer or higher polymer.
[0065] As used herein, the term "Igha gene" (also referred to as immunoglobulin heavy chain constant region α) encodes the constant region of the IgA heavy chain. Specifically, the term "Igha1 gene" or "IGHA1 gene", also referred to as immunoglobulin heavy chain constant region α1, encodes the constant region of the IgA1 heavy chain.
[0066] The human IGHA1 gene is located on human chromosome 14, and an exemplary genomic sequence can be found under NCBI gene ID number 3493 (assembly GRCh38.p14; position NC_000014.9 (c105708664-105707168), and its sequence is shown in SEQ ID NO: 19). Another exemplary genomic sequence of the human IGHA1 gene is shown in SEQ ID NO: 33 (IGHA1-202 (ENST00000641837.1 from Ensembl)). In some embodiments, the wild-type human IgA1 heavy chain constant region encoded by the human IGHA1 gene has been assigned UniProtKB / Swiss-Prot: P01876.2 (its sequence is shown in SEQ ID NO: 20). In some embodiments, the wild-type human IgA1 heavy chain constant region encoded by the human IGHA1 gene has been assigned UniProtKB: A0A286YEY1 (its sequence is shown in SEQ ID NO: 34). At least five isotypes of human IgA1 heavy chain constant regions are known in the art and have been assigned GenBank: AAF03879.1 (its sequence is shown in SEQ ID NO: 21), GenBank: AAT74070.1 (its sequence is shown in SEQ ID NO: 22), GenBank: AAX09631.2 (its sequence is shown in SEQ ID NO: 23), GenBank: AAX09630.2 (its sequence is shown in SEQ ID NO: 24) and GenBank: ABI26625.1 (its sequence is shown in SEQ ID NO: 25).
[0067] The mouse Igha gene is located on mouse chromosome 12, and an exemplary genomic sequence can be found under NCBI Gene ID 238447 (NC_000078.7 references GRCm39 C57BL / 6J (c113223856-113219824), and its sequence is shown in SEQ ID NO: 26). The wild-type mouse IgA heavy chain constant region encoded by the mouse Igha gene has been assigned UniProtKB / Swiss-Prot: P01878.1 (its sequence is shown in SEQ ID NO: 27). At least five isotypes of mouse IgA heavy chain constant regions are known in the art and have been assigned GenBank: AAL15539.1 (whose sequence is shown in SEQ ID NO: 28), GenBank: AAL15541.1 (whose sequence is shown in SEQ ID NO: 29), GenBank: AAL15540.1 (whose sequence is shown in SEQ ID NO: 30), GenBank: AAL15543.1 (whose sequence is shown in SEQ ID NO: 31), and GenBank: AAL15542.1 (whose sequence is shown in SEQ ID NO: 32), respectively.
[0068]
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076] As used herein, the term "endogenous locus" or "endogenous gene" refers to a genetic locus found in a parent or reference organism prior to the introduction of an alteration, interruption, deletion, insertion, modification, substitution, or replacement described herein. In some embodiments, the endogenous locus comprises all or part of a sequence found in nature. In some embodiments, the endogenous locus is a wild-type locus. In some embodiments, the reference organism is a wild-type organism. In some embodiments, the reference organism is an engineered organism. In some embodiments, the reference organism is a laboratory-bred organism (whether wild-type or engineered). For example, an "endogenous Igha locus" of a non-human animal (e.g., a mouse or rat) refers to a natural Igha locus that is naturally present in the non-human animal (e.g., a mouse or rat).
[0077] The term "wild-type" or "WT" includes an entity having a structure and / or activity found in a normal (as opposed to mutated, diseased, altered, etc.) state or environment. Wild-type genes and polypeptides typically exist in multiple different forms (e.g., alleles).
[0078] The terms "nucleic acid" and "polynucleotide" are used interchangeably herein and refer to a polymer form of nucleotides of any length in single-stranded or double-stranded form (deoxyribonucleotides (DNA) or ribonucleotides (RNA) or their analogs). Polynucleotides can have any three-dimensional structure and can perform any known or unknown function. Non-limiting examples of polynucleotides include genes, gene fragments, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, shRNA, single-stranded short or long RNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, DNA separated from any sequence, control regions, RNA separated from any sequence, nucleic acid probes and primers. Nucleic acid molecules can be linear or circular. Unless otherwise indicated, specific polynucleotide sequences also implicitly encompass conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs and complementary sequences and sequences explicitly indicated. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (see Batzer et al., Nucleic Acids Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
[0079] The terms "protein", "polypeptide" and "peptide" are used interchangeably and refer to polymers of amino acids. The proteins, polypeptides or peptides described herein may contain naturally occurring amino acids, or may contain non-naturally occurring amino acids, or analogs or mimetics of amino acids. The proteins, polypeptides or peptides described herein may be obtained by any method known in the art, such as, but not limited to, natural isolation, recombinant expression, chemical synthesis, etc.
[0080] As used herein, the term "amino acid" refers to an organic compound containing amino (-NH2) and carboxyl (-COOH) functional groups and side chains unique to each amino acid. Amino acid names are also represented in this disclosure as standard single-letter or three-letter codes, which are summarized below.
[0081]
[0082]
[0083] The phrase "heavy chain" or "immunoglobulin heavy chain" includes immunoglobulin heavy chain sequences from any organism, including immunoglobulin heavy chain constant region sequences. Unless otherwise indicated, the heavy chain variable region includes three heavy chain complementary determining regions (CDRs) and four FR regions. The fragment of the heavy chain includes CDRs and FRs and combinations thereof. A typical heavy chain has a CH1 domain, a hinge, a CH2 domain, a CH3 domain, and a CH4 domain (in the case of IgM or IgE) after the variable region (from N-terminal to C-terminal). The functional fragment of the heavy chain includes a fragment that can specifically recognize an epitope (e.g., recognize an epitope with a KD in a micromolar, nanomolar or picomolar range), can be expressed and secreted from a cell and includes at least one CDR.
[0084] The term "heterologous" refers to a preparation or entity from a different source. For example, when used to refer to a polypeptide, gene or gene product present in a specific cell or organism, the term explains that the relevant polypeptide or fragment thereof, gene or fragment thereof, or gene product or fragment thereof: 1) is artificially engineered; 2) is introduced into a cell or organism (or its precursor) artificially (e.g., by genetic engineering); and / or 3) is not naturally produced by or present in a related cell or organism (e.g., a related cell type or organism type). As used herein, the term "heterologous" also includes polypeptides or fragments thereof, genes or fragments thereof, or gene products or fragments thereof, which are usually present in a specific natural cell or organism, but have been modified, for example, by mutation or substitution under the control of a non-naturally related and, in some embodiments, non-endogenous regulatory element (e.g., a promoter).
[0085] When referring to protein, the term "fragment" means a protein shorter than the full-length protein or with fewer amino acids. When referring to nucleic acids, the term "fragment" means a nucleic acid shorter than the full-length nucleic acid or with fewer nucleotides. When referring to protein fragments, fragments can be, for example, N-terminal fragments (i.e., removing a portion of the C-terminal of the protein), C-terminal fragments (i.e., removing a portion of the N-terminal of the protein) or internal fragments (i.e., removing a portion of each end in the N-terminal and C-terminal of the protein). When referring to nucleic acid fragments, fragments can be, for example, 5' fragments (i.e., removing a portion of the 3' end of the nucleic acid), 3' fragments (i.e., removing a portion of the 5' end of the nucleic acid) or internal fragments (i.e., removing a portion of each end in the 5' end and 3' end of the nucleic acid).
[0086] In the context of inserting a nucleic acid sequence into a cell, the term "introducing" refers to "transfection" or "transformation" or "transduction", and includes reference to incorporating a nucleic acid sequence into a cell, wherein the nucleic acid sequence may be transiently present in the cell or may be incorporated into the genome (e.g., chromosome, plasmid, plastid or mitochondrial DNA) of the cell, converted into an autonomous replicon. The nucleic acid sequence may be introduced into the cell using any method known in the art. A variety of techniques for transforming animal cells may be employed, including, for example, microinjection, retroviral-mediated gene transfer, electroporation, transfection, and the like (see, e.g., Keown et al., Methods in Enzymology 1990, 185: 527-537).
[0087] As used herein, the term "chimeric" refers to an antibody or antigen-binding fragment having a portion of a heavy chain and / or light chain derived from one species, and the remainder of the heavy chain and / or light chain derived from a different species. In an illustrative example, a chimeric antibody may include a constant region derived from a human and a variable region derived from a non-human animal such as a mouse, rat, rabbit, goat, sheep, guinea pig, or hamster.
[0088] The term "non-human animal" refers to any non-human organism. For example, the non-human animal can be a livestock animal, such as a cow, pig, sheep, goat, poultry, or horse; or a rodent, such as a rat or mouse; or a primate, such as an ape, monkey, chimpanzee, gorilla, orangutan, baboon; or a domesticated animal, such as a dog or cat.
[0089] The terms "5' regulatory region" and "3' regulatory region" as used herein include regulatory elements found in the 5' upstream region and 3' downstream region of a gene. The term "regulatory element" includes transcriptional regulatory sequences, including both 5' transcriptional regulatory sequences (such as promoters, enhancers and repressor elements) and 3' transcriptional regulatory sequences (such as transcription termination sequences). The term "regulatory element" also includes regulatory sequences in the 5' untranslated region (5'UTR) and 3'UTR, which may affect the efficiency of transcription and the stability of the transcript, as well as the initiation of translation.
[0090] As used herein, "CRISPR-Cas guide RNA" or "guide RNA", "gRNA" or "sgRNA" refers to an RNA that guides the sequence-specific binding of a CRISPR complex to a target sequence. Typically, the guide RNA includes (i) a guide sequence that has sufficient complementarity to a target polynucleotide sequence to hybridize with the target sequence and (ii) a trans-activating cr (tracr) pairing sequence. The guide RNA may further include a tracr RNA fused to the 3' end, thereby producing a single chimeric guide RNA. In some embodiments, when optimally aligned using a suitable alignment algorithm, the degree of complementarity between the guide sequence and its corresponding target sequence is about or greater than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99% or more. Optimal alignment can be determined by using any suitable algorithm for aligning sequences, non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler transformation (e.g., the BurrowsWheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies), ELAND (Illumina, San Diego, Calif.), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net). In some embodiments, the guide sequence is about or greater than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75 or more nucleotides in length. In some embodiments, the guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, 11, 10 or fewer nucleotides in length. The ability of a guide sequence to direct sequence-specific binding of a CRISPR complex to a target sequence can be assessed by any suitable assay. For example, components of a CRISPR system sufficient to form a CRISPR complex (including the guide sequence to be tested) can be provided to a host cell with the corresponding target sequence, such as by transfection with a vector encoding the components of the CRISPR sequence, and then preferential cleavage within the target sequence can be assessed.Similarly, cleavage of a target polynucleotide sequence can be assessed in a test tube by providing a target sequence, components of a CRISPR complex (including the guide sequence to be tested), and a control guide sequence different from the test guide sequence, and comparing the binding or cleavage rate at the target sequence between the test and control guide sequence reactions. Other assays are possible and will occur to those skilled in the art.
[0091] The term "embryonic stem (ES) cell" as used herein refers to a pluripotent cell separated from the inner cell mass of a developing blastocyst, or the offspring of these cells."ES cell" can be derived from any organism.ES cells can be derived from mammals, including mice, rats, rabbits, guinea pigs, goats, pigs, cattle, monkeys and humans. In a specific non-limiting example, the cell is a human or non-human (e.g., mouse) cell. Without being bound by theory, ES cells can produce various cells (skeletal, muscle, brain cells, etc.) present in vivo, provided that they are exposed to conditions conducive to developing these cell types. The method for producing mouse ES cells can be found in U.S. Patent No. 5,670,372, which is incorporated herein by reference. The method for producing human ES cells can be found in U.S. Patent No. 6,090,622, WO 00 / 70021 and WO00 / 27995, which are incorporated herein by reference.
[0092] II. Methods for Producing Genetically Modified Non-Human Animals
[0093] In one aspect, the present disclosure provides a method for preparing a non-human animal, the non-human animal comprising a genetically modified endogenous Igha locus in its genome, the locus comprising a heterologous gene encoding a human IgA (e.g., IgA1) heavy chain constant region or a fragment thereof. Specifically, the present disclosure provides a method for preparing a genetically modified non-human animal, the method comprising: (i) modifying the genome of a non-human animal to incorporate nucleotides comprising a heterologous gene into its endogenous Igha locus, the heterologous gene encoding a human IgA heavy chain constant region or a fragment thereof; and (ii) treating the non-human animal produced in step (i) with a formulation comprising an immunostimulant.
[0094] Step (i)
[0095] In some embodiments, step (i) of the method provided herein comprises introducing nucleotides comprising a heterologous gene encoding a human IgA heavy chain constant region or a fragment thereof into pluripotent cells of a non-human animal, thereby obtaining non-human animal pluripotent cells comprising the heterologous gene, and using the non-human animal pluripotent cells comprising the heterologous gene to prepare a non-human animal.
[0096] The nucleotides comprising the heterologous genes encoding human IgA heavy chain constant region or its fragment can be prepared by using methods well known in the art. For example, nucleotide molecules can be prepared as part of a larger plasmid. This preparation allows cloning and separation of the correct construct in an efficient manner known in the art. The various methods used in preparing plasmids and transforming host organisms are known in the art (see, for example, "Molecular Cloning: Laboratory Manual (Molecular Cloning ALaboratory Manual)", 2nd Edition, Sambrook et al., edited, Cold Spring Harbor Laboratory Press (Cold Spring Harbor Laboratory Press), 1989). In addition, yeast artificial chromosomes (YAC) can be used to separate, clone and transfer the entire locus of the desired heterologous genes encoding human IgA heavy chain constant region or its fragment. Alternatively, bacterial artificial chromosome (BAC) libraries (see, for example, the genomic BAC library from Invitrogen, Carlsbad Calif., California) can provide the nucleotide sequence and regulatory sequence of the desired heterologous genes encoding human IgA heavy chain constant region or its fragment.
[0097] The prepared transgenic construct can be introduced into pluripotent cells (e.g., ES cells) using any method known in the art. Various techniques for transforming mammalian cells can be used in the present invention, including, for example, microinjection, retroviral-mediated gene transfer, electroporation, transfection, etc. (see, for example, Gordon, Intl. Rev Cytol., 1 15: 171 (1989); Keown et al., Enzymology, 185: 527-537 (1990); Mansour et al., Nature, 336: 348-352 (1988)).
[0098] Methods for modifying non-human animal genomes (e.g., pigs, cattle, rodents, chickens, etc.) include, for example, using zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) or Cas proteins (i.e., CRISPR / Cas systems) to modify genomes to include heterologous genes encoding human IgA heavy chain constant regions or fragments thereof as described herein. Guidance for methods for modifying germline genomes of non-human animals can be found in, for example, U.S. Patent Publications No. US20150376628A1, No. US20160145646A1, and No. US20160177339A1, all of which are incorporated herein by reference.
[0099] In some embodiments, nucleotides containing heterologous genes are introduced into pluripotent cells of non-human animals by using a CRISPR / Cas system. In some embodiments, the CRISPR / Cas system is a CRISPR / Cas9 system. In some embodiments, the CRISPR / Cas9 system comprises a Cas9 protein and a guide RNA, and the guide RNA targets a guide RNA target sequence in an endogenous Igha locus. In some embodiments, the CRISPR / Cas9 system used in the present application comprises a Cas9 protein and one, two or more, three or more, or four or more guide RNAs targeting a guide RNA target sequence in an endogenous Igha locus. For example, the CRISPR / Cas9 system used in the present application comprises a Cas9 protein and a guide RNA, and the guide RNA includes any one, two, three or four sequences in the sequence shown in SEQ ID NO: 9 to 12. In some embodiments, the CRISPR / Cas system is a CRISPR / Cas13 system. In some embodiments, the CRISPR / Cas13 system comprises a Cas13 protein and a guide RNA, and the guide RNA targets a guide RNA target sequence in an endogenous Igha locus. In some embodiments, the CRISPR / Cas13 system used in the present application comprises a Cas13 protein and one, two or more, three or more, or four or more guide RNAs targeting a guide RNA target sequence within an endogenous Igha locus.
[0100] Pluripotent cells as described herein may include undifferentiated cells with the ability to develop into more than one differentiated cell type. Such pluripotent cells may be, for example, embryonic stem (ES) cells or ES-like cells, such as induced pluripotent stem (iPS) cells. In some embodiments, the pluripotent cells are embryonic stem (ES) cells. ES cells are included in embryonic-derived pluripotent cells that can contribute to any tissue of the developing embryo when introduced into the embryo. ES cells may be derived from the inner cell mass of the blastocyst, and may be differentiated into the cells of any layer in the three vertebrate germ layers (endoderm, ectoderm and mesoderm). ES cells with desired nucleotides may be selected to be incorporated into endogenous Igha loci. In some embodiments, one or more copies of nucleotides may be incorporated at one or more specific sites; and in some embodiments, a copy of nucleic acid may be incorporated at a specific site.
[0101] ES cells are typically obtained from preimplantation embryos cultured in vitro (see, e.g., Evans, MJ. et al., Nature 292:154-156 (1981); Bradley, MO et al., Nature 309:255-258 (1984); Gossleer et al., Proc. Natl. Acad. Sci. USA 83:9065-9069 (1986); Robertson et al., Nature 322:445-448 (1986)). ES cells are cultured and prepared for the introduction of transgenic constructs using methods well known in the art (see, e.g., Teratocarcinomas and Embryonic Stem cells: a Practical Approach, Robertson, ed., IRL Press (1987); Bradley et al., Current Topics in Devel. Biol. 20:357-371 (1986); Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1986); Thomas et al., Cell 51:503 (1987); Koller et al., Proc. Natl. Acad. Sci. USA 88:10730 (1991); Donn et al., Transgenic Research 51:10731 (1991); Res.)》1:101(1992;Veis et al., "Cell" 75:229(1993)). The ES cells into which the desired heterologous gene encoding the human IgA heavy chain constant region or a fragment thereof is inserted are derived from embryos or blastocysts of the same species as the developing embryo into which it will be introduced. ES cells are generally selected for their ability to integrate into the inner cell mass and contribute to the reproductive system of the individual when introduced into the embryo of a host animal at the blastocyst stage of development. Therefore, any ES cell line having this ability is suitable for use in the practice of the present invention.
[0102] The selected ES cells are then injected into the embryos of animals (suitable for producing blastocysts or other developmental stages of viable animals) to produce chimeras (see, e.g., Teratocarcinoma and Embryonic Stem Cells: A Practical Approach, edited by EJ.Robertson, Oxford IRL Press, pp. 13-152 (1987)). Alternatively, the selected cells can be aggregated with dissociated embryonic cells to form aggregated chimeras. The chimeric embryos can then be implanted in suitable pseudo-pregnant female foster animals, and the embryos are brought to term. The chimeric offspring contain the desired human genes in their germ cells and can be used to cultivate animals, wherein all cells of the animal contain the desired human genes. Then, ES cells with the desired nucleotides incorporated into the endogenous Igha locus are used as donor ES cells. In some embodiments, embryos comprising donor ES cells are implanted in pseudo-pregnant females to produce F0 non-human animals.
[0103] In other embodiments, a non-human animal comprising a genetically modified endogenous Igha locus in its genome can be prepared without using ES cells, and the locus comprises a heterologous gene. For example, the genome of a non-ES cell (e.g., a fibroblast or an induced pluripotent cell) can be modified based on a conventional transformation method (e.g., electroporation), and the modified genome of this non-ES cell can be transferred to a suitable recipient cell, such as an oocyte, by using a nuclear transfer technique. The modified cell (e.g., a modified oocyte) is then bred under suitable conditions to form an embryo. See, for example, Han et al., Methods in Enzymology 476: 171-184 (2010) and Zhou et al., Science 302: 1179 (2003).
[0104] In some embodiments, the non-human animal is a rodent, a mammal, or a non-human primate. In some embodiments, the non-human animal is a male animal. In some embodiments, the non-human animal is a female animal. In some embodiments, the non-human animal is a mouse or a rat.
[0105] In some embodiments, the rodent is a mouse. In some embodiments, the rodent is a mouse of a C57BL strain (e.g., a C57BL strain selected from C57BL / A, C57BL / An, C57BL / GrFa, C57BL / KaLwN, C57BL / 6, C57BL / 6J, C57BL / 6ByJ, C57BL / 6NJ, C57BL / 10, C57BL / 10ScSn, C57BL / 10Cr, and C57BL / 01a). In other embodiments, the rodent is a 129 strain mouse (e.g., a 129 strain selected from the group consisting of 129P1, 129P2, 129P3, 129X1, 129S1 (e.g., 129S1 / SV, 129S1 / SvIm), 129S2, 129S4, 129S5, 129S9 / SvEvH, 129 / SvJae, 129S6 (129 / SvEvTac), 129S7, 129S8, 129T1, 129T2) (see, e.g., Festing et al., (1999), Mammalian Genome 10:836; Auerbach et al. (2000), Biotechniques 29(5):1024-1028, 1030, 1032). In some embodiments, rodent is a mouse of a mixture of the aforementioned 129 strain and the aforementioned C57BL / 6 strain. In certain embodiments, mouse is a mixture of the aforementioned 129 strain (i.e., hybridization) or a mixture of the aforementioned C57BL strain or a mixture of the C57BL strain and the 129 strain. In certain embodiments, mouse is a mixture of the C57BL / 6 strain and the 129 strain. In a specific embodiment, mouse is a VGF1 strain, also referred to as F1H4, which is a hybrid of C57BL / 6 and 129. In other embodiments, mouse is a BALB strain, such as a BALB / c strain. In some embodiments, mouse is a mixture of the BALB strain and another aforementioned strain.
[0106] In some embodiments, the rodent is a rat. In certain embodiments, the rat is selected from Wistar rat, LEA strain, Sprague Dawley strain, Fischer strain, F344, F6 and Dark Agouti. In other embodiments, the rat is a mixture of two or more strains selected from the group consisting of Wistar, LEA, Sprague Dawley, Fischer, F344, F6 and Dark Agouti.
[0107] In some embodiments, a segment or all of an endogenous non-human animal Igha gene at an endogenous non-human animal Igha locus has been deleted. In some embodiments, a segment or all of an endogenous non-human animal Igha gene at an endogenous non-human animal Igha locus has been deleted and replaced with nucleotides of a heterologous gene encoding a human IgA heavy chain constant region or a fragment thereof. In some embodiments, the non-human animals described herein do not express an endogenous non-human IgA heavy chain constant region.
[0108] Preferably, replacement of the endogenous non-human animal Igha gene with the corresponding human IGHA1 gene can be achieved by homologous recombination (see, for example, Allen et al., Eur J Neurosci 17, 1881-1895 (2003); Makita et al., Am J Physiol Renal Physiol 294, F542-F553 (2008)). Alternative targeting constructs are often used for homologous gene replacement. In order to prepare an alternative targeting construct, the nucleic acid sequence of the desired human IGHA1 gene is flanked between two homologous recombination sequences derived from non-human animal genomic sequences. The double exchange between the homologous recombination sequence of the targeting construct and the non-human animal genomic sequence enables the targeted integration of the nucleic acid sequence of the desired human IGHA1 gene into the locus of the corresponding non-human animal Igha gene in animal cells. Typically, the homologous recombination sequence of the targeting construct includes sequences flanking the endogenous non-human animal Igha gene segment, such that homologous recombination causes concomitant deletion of the endogenous non-human animal Igha gene segment and homologous integration of the desired human IGHA1 gene segment (see Roebroek et al., Trangenic Mouse Methods and Protocols, Hofker and van Deursen, eds., Methods in Mol Biol, 693: 257-275 (2011)). The entire or segment of the endogenous non-human animal Igha gene can be replaced by the desired human IGHA1 gene by a single targeting event or by multiple targeting events that sequentially replace individual exons. One or more selectable markers (e.g., positive or negative selectable marker genes) can be used in the targeting construct. It is generally preferred that the selectable marker is located in an intronic region of the desired human IGHA1 gene.
[0109] In some embodiments, replacement of the endogenous non-human animal Igha gene with the corresponding human IGHA1 gene can be achieved by using a site-specific recombination system (e.g., a Cre / LoxP system or a Flp / FRT system; see Roebroek et al., Transgenic Mouse Methods and Protocols, Hofker and van Deursen, eds., Methods in Molecular Biology, 693:257-275 (2011)). As a starting point for this strategy, two recombinase recognition sequences (e.g., LoxP, FRT or attB / attP sequences) are introduced into appropriate non-human animal cells (e.g., ES cells) by a first homologous recombination event, such that the two introduced recombinase recognition sequences flank the endogenous non-human animal Igha gene. In the first homologous recombination event, a selection marker gene (e.g., HygTK) is typically introduced into the non-human animal cell, thereby allowing positive selection (e.g., by hygromycin B) and negative selection (e.g., by ganciclovir). A transgenic construct carrying a desired human IGHA1 gene corresponding to an endogenous non-human animal Igha gene is prepared so that the desired human IGHA1 gene is flanked by two recombinase recognition sites. The transgenic construct is then introduced into the targeted non-human animal cell produced by the first homologous recombination event. A recombinase source is provided to trigger site-specific recombination, which causes the exchange of the desired human IGHA1 gene with the endogenous animal Igha gene. The recombinase recognition sequence can remain present in the locus after the exchange, and is preferably not present in the protein coding region.
[0110] In some embodiments, the heterologous gene encoding the human IgA1 heavy chain constant region or its fragment is a genomic fragment of the human IGHA1 gene. In some embodiments, the heterologous gene only comprises the human IGHA1 coding sequence. In some embodiments, the heterologous gene comprises both the human IGHA1 coding sequence and the non-coding sequence. In some embodiments, the heterologous gene comprises the entire human IGHA1 coding sequence from ATG to STOP, with 5' and 3' untranslated regions and the introns in the middle. In some embodiments, the human IgA1 heavy chain constant region of a non-human animal comprises an O-glycosylated hinge region. In some embodiments, the heterologous gene is a human IGHA1 gene encoding the human IgA1 heavy chain constant region or its fragment.
[0111] A nucleic acid sequence is "operably linked" when it is placed in a functional relationship with another nucleic acid sequence. For example, if a promoter or a 5' regulatory region containing a promoter affects the transcription of a coding sequence, then the promoter or 5' regulatory region is considered to be operably linked to a coding sequence.
[0112] In some embodiments, a heterologous gene encoding a human IgA heavy chain constant region or a fragment thereof is inserted into the same locus as the corresponding endogenous non-human animal Igha gene, so that the expression of the heterologous gene is controlled by the transcriptional regulatory elements of the corresponding endogenous non-human animal Igha gene. The heterologous gene can be contained in a nucleotide. In some embodiments, the nucleotide is operably connected to the endogenous regulatory elements (e.g., promoters, enhancers, silencers, etc.) of the non-human animal. Examples of such transcriptional regulatory elements include, but are not limited to, promoters, enhancers, silencers, and start signals. In some embodiments, a humanized transgenic non-human animal containing a human IGHA1 gene can be prepared so that the protein coding sequence of the human IGHA1 gene is inserted into the locus of the endogenous non-human animal Igha gene. The insertion can be performed by recombination so that the protein coding sequence of the introduced human IGHA1 gene replaces the corresponding protein coding sequence of the non-human Igha gene. This allows the expression of the introduced human IGHA1 gene to be controlled by the transcriptional regulatory elements of the endogenous non-human animal Igha gene.
[0113] In some embodiments, the nucleotide sequence may further comprise a 3' regulatory region operably linked to a heterologous gene encoding a human IgA1 heavy chain constant region or a fragment thereof.
[0114] In some embodiments, the 3' regulatory region comprises a 3' UTR. In some embodiments, the 3' regulatory region comprises a 3' UTR of a heterologous gene encoding a human IgA1 heavy chain constant region or a fragment thereof.
[0115] In some embodiments, the 3' regulatory region includes a sequence upstream of the 3'UTR of the heterologous gene. In some embodiments, the 3' regulatory region includes a nucleotide sequence immediately upstream of the 3'UTR of the heterologous gene and is at least 50 bp, at least 100 bp, at least 150 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 750 bp, at least 1000 bp or longer (e.g., up to 2500-4000 bp).
[0116] In some embodiments, the 3' regulatory region includes a sequence downstream of the 3'UTR of the heterologous gene. In some embodiments, the 3' regulatory region includes a nucleotide sequence immediately downstream of the 3'UTR of the heterologous gene and is at least 50 bp, at least 100 bp, at least 150 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 750 bp, at least 1000 bp or longer (e.g., up to 2500-4000 bp).
[0117] In some embodiments, the nucleotide sequence may further comprise a 5' regulatory region, which is operably linked to a heterologous gene encoding a human IgA1 heavy chain constant region or a fragment thereof.
[0118] In some embodiments, the 5' regulatory region comprises a 5' UTR. In some embodiments, the 5' regulatory region comprises a 5' UTR of a heterologous gene encoding a human IgA1 heavy chain constant region or a fragment thereof.
[0119] In some embodiments, the 5' regulatory region includes a sequence upstream of the 5'UTR of the heterologous gene. In some embodiments, the 5' regulatory region includes a nucleotide sequence immediately upstream of the 5'UTR of the heterologous gene and is at least 50 bp, at least 100 bp, at least 150 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 750 bp, at least 1000 bp or longer (e.g., up to 2500-4000 bp).
[0120] In some embodiments, the 5' regulatory region includes a sequence downstream of the 5'UTR of the heterologous gene. In some embodiments, the 5' regulatory region includes a nucleotide sequence immediately downstream of the 5'UTR of the heterologous gene and is at least 50 bp, at least 100 bp, at least 150 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 750 bp, at least 1000 bp or longer (e.g., up to 2500-4000 bp).
[0121] In some embodiments, modification of the non-human animal genome or incorporation of nucleotides into the non-human animal results in structural changes to the endogenous Igha locus. In some embodiments, a segment or all of an endogenous non-human animal Igha gene at the endogenous non-human animal Igha locus is silenced. In some embodiments, a segment or all of an endogenous non-human animal Igha gene at the endogenous non-human animal Igha locus has been deleted and replaced with nucleotides comprising a heterologous gene.
[0122] When the normal protein product expressed from a gene is suppressed, the gene is "silenced". A gene is usually silenced by disrupting the genomic sequence of the gene. When DNA fragments are located and recombined with endogenous homologous sequences, a gene is disrupted. Disruption can include insertion, missense, frameshift, deletion, or substitution, or replacement, or any combination thereof of a DNA sequence. When disruption can change a normal gene product by partially or completely suppressing the production of a normal gene product, insertion includes insertion of the entire gene. In a preferred embodiment, disruption is ineffective disruption so that the gene is not significantly expressed.
[0123] The term "replace / replacement" as used herein means that in a transgenic non-human animal into which a desired human gene is introduced, the endogenous non-human animal gene corresponding to the introduced human gene is silenced, so that the introduced human gene functionally replaces the corresponding animal gene. For example, in a humanized transgenic mouse into which the human Igha1 gene is introduced, the endogenous mouse Igha gene is further silenced, so that the introduced human IgA1 protein functionally replaces the mouse IgA1 protein.
[0124] In some embodiments, the modification of the non-human animal genome causes a functional change in the endogenous Igha locus. In some embodiments, the non-human animal does not express an endogenous non-human IgA heavy chain constant region. In some embodiments, the non-human animal produces a chimeric IgA1, the heavy chain of which comprises a non-human animal variable region and a human constant region or a fragment thereof.
[0125] Step (ii)
[0126] In step (ii) of the methods provided herein for preparing a genetically modified non-human animal, the non-human animal produced in step (i) above is treated with a formulation comprising an immunostimulant.
[0127] An "immunostimulant" is any substance that stimulates the immune system by inducing activation or increasing the activity of any component of the immune system, particularly immune effector cells. Immunostimulants can be pro-inflammatory (e.g., when treating infection or cancer) or anti-inflammatory (e.g., when treating autoimmune diseases).
[0128] In some embodiments, the immunostimulatory agent includes an adjuvant immunostimulatory agent, such as an APC Toll-like receptor agonist or a costimulatory / cell adhesion membrane protein. Examples of Toll-like receptor agonists include costimulatory / adhesion proteins, such as CD80, CD86, and ICAM-1. In some embodiments, the immunostimulatory agent used in the present invention is selected from the group consisting of: aluminum adjuvants, emulsion adjuvants, biological adjuvants, and saponins.
[0129] In some embodiments, the aluminum adjuvant is selected from the group consisting of aluminum hydroxide (Al(OH)3), aluminum phosphate, aluminum hydroxyphosphate, and amorphous aluminum hydroxyphosphate sulfate (AAHS). In some embodiments, the aluminum adjuvant is aluminum hydroxide.
[0130] In some embodiments, the emulsion adjuvant is an oil-in-water emulsion adjuvant or a water-in-oil emulsion adjuvant. In some embodiments, the emulsion adjuvant is selected from the group consisting of: Freund's complete adjuvant (CFA), Freund's incomplete adjuvant, MF59 and AS03. In some embodiments, the immunostimulant used in the present invention is CFA. Various commercial CFAs are available for public use, for example, purchased from products such as Sigma-Aldrich, Merck, etc. In some embodiments, the CFA used in the present invention is purchased from Sigma (SIGMA) (catalog # F5881). In some embodiments, the CFA used in the present invention contains Mycobacterium tuberculosis, paraffin oil and mannide monooleate. In some embodiments, each mL of CFA used in the present invention contains 0.5-5 mg (e.g., 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, or 5 mg) of heat-killed and dried Mycobacterium tuberculosis, 0.1-1 mL (e.g., 0.5 mL, 0.85 mL, 1 mL) of paraffin oil, and 0.05-1 mL (e.g., 0.1 mL, 0.15 mL, 0.2 mL, 0.3 mL, 0.4 mL, 0.5 mL, 0.6 mL, 0.7 mL, 0.8 mL, 0.9 mL, or 1 mL) of mannide monooleate. In some embodiments, each mL of CFA used in the present invention contains 1 mg of heat-killed and dried Mycobacterium tuberculosis (H37Ra, ATCC 25177), 0.85 mL of paraffin oil, and 0.15 mL of mannide monooleate.
[0131] In some embodiments, the biological adjuvant is selected from the group consisting of: lipopolysaccharide or a derivative thereof, a toll-like receptor (TLR) agonist (e.g., TLR4 ligand, TLR7 ligand, TLR8 ligand, TLR9 ligand), an immunostimulatory oligonucleotide (e.g., DNA or dsRNA containing CpG), a cytokine (e.g., IL-2, IL-7, IL-12, IL-15 and IL-23) or a variant thereof, an interferon (e.g., IFN-α or IFN-γ), a colony stimulating factor (e.g., M-CSF and GM-CSF), a tumor necrosis factor, an endotoxin, and a lipid (e.g., lipid A or its analogs). In some embodiments, the biological adjuvant is lipopolysaccharide or a derivative thereof.
[0132] In some embodiments, the formulation used to treat the non-human animal produced in step (i) comprises an immunostimulatory agent and an antigen.
[0133] The term "antigen" refers to a preparation comprising an epitope that can generate an immune response. Specifically, the term "antigen" includes proteins and peptides. In some embodiments, the antigen is a disease-associated antigen, such as a viral antigen or a bacterial antigen, and the epitope is derived from such an antigen.
[0134] The term "viral antigen" refers to any viral component that has antigenic properties (ie, is capable of eliciting an immune response in an individual). A viral antigen may be a viral ribonucleoprotein or an envelope protein.
[0135] The term "bacterial antigen" refers to any bacterial component having antigenic properties (i.e., capable of eliciting an immune response in an individual). Bacterial antigens can be derived from the cell wall or cytoplasmic membrane of bacteria. In some embodiments, the antigen used in the present invention is derived from a bacterial cell wall extract. In some embodiments, the antigen includes a rhamnose source. In some embodiments, the rhamnose source is a Lactobacillus casei cell wall extract (LCWE).
[0136] In some embodiments, the non-human animal produced in step (i) is treated with a formulation comprising LCWE emulsified with CFA. Detailed treatment with LCWE can be performed using conventional means in the art (see Duong TT, Silverman ED, Bissessar MV et al., International Immunology, 2003(1):15; Noval Rivas et al., Immunity, 2019(3):51; Suganuma E, Sato S, Honda S et al., Experimental Animals, 2020, 69(2)).
[0137] In some embodiments, the formulation is composed of an immunostimulant. For example, the non-human animal produced in step (i) is treated with a single CFA. The inventors of the present disclosure unexpectedly found that the non-human animal containing the humanized Igha locus produced in step (i) is sufficient to produce a genetically modified non-human animal with a single (e.g., antigen-free) immunostimulant (e.g., CFA) treatment, which is sufficient to produce a genetically modified non-human animal, wherein the genetically modified non-human animal shows clinical signs of a disease associated with IgA deposition (e.g., IgA nephropathy), for example, compared to wild-type non-human animals, IgA1 is increased, galactose-deficient IgA1 (Gd-IgA1) is increased, IgA1 / C3 glomerular deposition, mesangial cell excess, capillary endocellularity, segmental sclerosis and / or crescents.
[0138] The formulation comprising the immunostimulant can be administered to the non-human animal produced in step (i) by any route known in the art, such as by parenteral routes (including subcutaneous, intraperitoneal, intravenous, intramuscular or intradermal injection) or non-parenteral routes (including transdermal, oral, intranasal, intraocular, sublingual, rectal or topical). In some embodiments, in step (ii), the formulation is injected intraperitoneally into the non-human animal produced in step (i).
[0139] Without being bound by any theory, it is believed that sustained delivery (e.g., sustained intraperitoneal delivery) or slow release of the formulation comprising the immunostimulant to the non-human animal produced in step (i) is advantageous for preparing a genetically modified non-human animal that exhibits clinical signs of a disease associated with IgA deposition (e.g., IgAN).
[0140] As used herein, the term "sustained delivery" refers to the continuous delivery of a formulation comprising an immunostimulatory agent in vivo over a certain period of time, preferably at least several days, a week or weeks, a month or months after administration.
[0141] In some embodiments, the formulation is injected intraperitoneally into the non-human animal produced in step (i) in continuous doses. In some embodiments, the formulation is injected intraperitoneally into the non-human animal produced in step (i) in continuous low doses. In some embodiments, the formulation comprises LCWE, and the formulation is injected intraperitoneally into the non-human animal produced in step (i) at a dose of less than 1 μg (e.g., less than 0.1 μg, less than 0.2 μg, less than 0.3 μg, less than 0.4 μg, less than 0.5 μg, less than 0.6 μg, less than 0.7 μg, less than 0.8 μg, less than 0.9 μg) LCWE per gram of non-human animal. In some embodiments, the formulation comprises or consists of CFA and the formulation is injected intraperitoneally into the non-human animal produced in step (i) at a dose of less than 5 μL (e.g., less than 4 μL, less than 3 μL, less than 2 μL, less than 1.9 μL, less than 1.8 μL, less than 1.7 μL, less than 1.6 μL, less than 1.5 μL, less than 1.4 μL, less than 1.3 μL, less than 1.2 μL, less than 1.1 μL, less than 1 μL, less than 0.9 μL, less than 0.8 μL, less than 0.7 μL, less than 0.6 μL, less than 0.5 μL, less than 0.4 μL, less than 0.3 μL, less than 0.2 μL, less than 0.1 μL) of CFA per gram of non-human animal. In some embodiments, the formulation comprises LCWE emulsified with CFA, and the formulation is prepared at a concentration of less than 1 μg (e.g., less than 0.1 μg, less than 0.2 μg, less than 0.3 μg, less than 0.4 μg, less than 0.5 μg, less than 0.6 μg, less than 0.7 μg, less than 0.8 μg, less than 0.9 μg) LCWE per gram of non-human animal and less than 5 μL (e.g., less than 4 μL, less than 3 μL, less than 2 μL, less than 1.9 μL, less than 1. The non-human animal produced in step (i) is injected intraperitoneally with a dose of CFA of less than 8 μL, less than 1.7 μL, less than 1.6 μL, less than 1.5 μL, less than 1.4 μL, less than 1.3 μL, less than 1.2 μL, less than 1.1 μL, less than 1 μL, less than 0.9 μL, less than 0.8 μL, less than 0.7 μL, less than 0.6 μL, less than 0.5 μL, less than 0.4 μL, less than 0.3 μL, less than 0.2 μL, less than 0.1 μL).
[0142] In some embodiments, the formulation is administered to the non-human animal produced in step (i) for at least one month. In some embodiments, the formulation is administered to the non-human animal produced in step (i) for at least two months. In some embodiments, the formulation is administered to the non-human animal produced in step (i) for at least three months. In some embodiments, the formulation is administered to the non-human animal produced in step (i) for at least four months.
[0143] In some embodiments, the formulation is applied to the non-human animal produced in step (i) at intervals of three times per week in the first two weeks and once per week in the next two weeks (i.e., eight times in a month) for a period of one month. In some embodiments, the formulation is applied to the non-human animal produced in step (i) at intervals of once every two weeks (i.e., six times in three months) for a period of three months. In some embodiments, the formulation is applied to the non-human animal produced in step (i) starting at 8 weeks of age and ending at 5 months, 6 months, 6.5 months, 7 months, 7.5 months, or 8 months of age.
[0144] In some embodiments, the non-human animal is a rodent, a mammal or a non-human primate. In some embodiments, the rodent is a mouse or a rat.
[0145] III. Genetically modified non-human animals
[0146] In another aspect, the present disclosure provides a non-human animal produced by the methods described herein. In another aspect, the present disclosure also provides a non-human cell or a non-human genome produced by the methods described herein.
[0147] In some embodiments, non-human animals, cells or genomes provided herein include genetically modified endogenous Igha loci in their genomes, the loci include heterologous genes encoding human IgA heavy chain constant regions or fragments thereof, wherein non-human animals show clinical signs of diseases associated with IgA deposition (e.g., IgA nephropathy). In some embodiments, non-human animals, cells or genomes provided herein include genetically modified endogenous Igha loci in their genomes, the loci include heterologous genes encoding human IgA heavy chain constant regions or fragments thereof, wherein non-human animals show clinical signs of IgA nephropathy.
[0148] In some embodiments, the non-human animals provided herein show histological lesions of IgA nephropathy. In some embodiments, the non-human animals provided herein show one or more histological lesions selected from the group consisting of: mesangial hypercellularity, endocapillary hypercellularity, segmental sclerosis, interstitial inflammation / tubular atrophy and crescents.
[0149] In some embodiments, the non-human animals provided herein show an increase in the level of galactose-deficient IgA proteins. In some embodiments, the non-human animals provided herein show an increase in the level of galactose-deficient IgA proteins in serum or intestinal mucus. In some embodiments, the "increase in the level" of galactose-deficient IgA proteins refers to an increase in the level of galactose-deficient IgA proteins compared to a reference level of galactose-deficient IgA proteins obtained from a wild-type corresponding non-human animal. The level of galactose-deficient IgA protein can be determined by methods well known in the art, such as Irabu H et al., J Immunol Res. 2020 May 21;2020:4284379; Suzuki H., Clin Exp Nephrol. 2019 Jan;23(1):26-31 and Neufeld M et al., J Am Acad Dermatol. 2019 Mar 19. pii:S0190-9622(19)30443-8, all of which are incorporated herein by reference in their entirety.
[0150] In some embodiments, the non-human animals described herein show an increase of at least 10-fold (e.g., at least 11-fold, at least 12-fold, at least 13-fold, at least 14-fold, at least 15-fold, at least 16-fold, at least 17-fold, at least 18-fold, at least 19-fold, at least 20-fold, at least 25-fold, or at least 30-fold) in galactose-deficient IgA proteins. In some embodiments, the non-human animals described herein show an increase of 10 to 20-fold in galactose-deficient IgA proteins with different renal pathology phenotypes, indicating that changes in glycosylation are closely related to the function of human IgA, rather than to the function of non-human (e.g., mouse) IgA under the same stimulus.
[0151] As described above, the method for preparing a genetically modified non-human animal provided herein can cause changes in the structure and / or function of an endogenous Igha locus in a non-human animal. In some embodiments, a segment or all of an endogenous non-human animal Igha gene at an endogenous non-human animal Igha locus has been deleted and replaced with a nucleotide comprising a heterologous gene. In some embodiments, the nucleotide comprising the heterologous gene is operably linked to an endogenous regulatory element (e.g., a promoter, an enhancer, a silencer, etc.) of a non-human animal. In some embodiments, the nucleotide comprising the heterologous gene is a genomic fragment of a human IGHA1 gene. In some embodiments, the heterologous gene comprises both a human IGHA1 coding sequence and a non-coding sequence. In some embodiments, the heterologous gene is a human IGHA1 gene encoding a human IgA1 heavy chain constant region or a fragment thereof. In some embodiments, the human IgA heavy chain constant region of a non-human animal provided herein comprises an O-glycosylated hinge region. In some embodiments, the non-human animal does not express an endogenous non-human IgA heavy chain constant region. In some embodiments, the non-human animal provided herein produces a chimeric IgA1, the heavy chain of which comprises a non-human animal variable region and a human constant region or a fragment thereof.
[0152] In some embodiments, the non-human animal is a rodent, a mammal or a non-human primate. In some embodiments, the rodent is a mouse or a rat.
[0153] IV. Uses of Genetically Modified Non-Human Animals
[0154] The non-human animals provided herein, e.g., non-human animals comprising a genetically modified endogenous Igha locus in the genome comprising a heterologous gene encoding a human IgA heavy chain constant region or a fragment thereof, can be used as animal models for diseases associated with IgA deposition, wherein the non-human animals display clinical signs of diseases associated with IgA deposition (e.g., IgA nephropathy).
[0155] In another aspect, the present disclosure further provides a method for evaluating the efficacy of a candidate drug for treating or preventing a disease associated with IgA deposition, the method comprising: providing a non-human animal as described herein; administering a candidate drug to the non-human animal; and evaluating whether the candidate drug inhibits one or more symptoms of the disease compared to a non-human animal control not administered with the candidate drug. If the candidate drug inhibits one or more symptoms of the disease compared to a non-human animal control not administered with the candidate drug, the candidate drug will be considered effective for treating or preventing a disease associated with IgA deposition.
[0156] In another aspect, the present disclosure provides a method for identifying a candidate drug for treating or preventing a disease associated with IgA deposition, the method comprising: providing a non-human animal as described herein; administering a candidate drug to the non-human animal; and evaluating whether the candidate drug inhibits one or more symptoms of the disease compared to a non-human animal control not administered with the candidate drug. If the candidate drug inhibits one or more symptoms of a disease associated with IgA deposition (e.g., IgA nephropathy), the candidate drug will be considered useful for treating or preventing a disease associated with IgA deposition.
[0157] In some embodiments, candidate drugs that can be evaluated or identified using the non-human animals provided herein include candidate inhibitors of IgA (e.g., IgA1), such as, but not limited to, small molecule inhibitors, nucleic acid-based inhibitors (e.g., siRNA, ribozymes, antisense constructs, etc.), antigen binding proteins (e.g., antibodies or antigen-binding fragments thereof), blocking peptides / peptide inhibitors, IgA protease or functional variants thereof, fusion proteins comprising IgA protease or functional variants thereof.
[0158] In some embodiments, the disease associated with IgA deposition is selected from the group consisting of: IgA nephropathy, dermatitis herpetiformis, Henlein-Schuh purpura (also known as IgA vasculitis), Kawasaki disease, purpuric nephritis, IgA vasculitis renal injury, IgA rheumatoid factor positive rheumatoid arthritis, IgA-mediated anti-GBM disease, or IgA-mediated ANCA-associated vasculitis. In some embodiments, the disease associated with IgA deposition is IgA nephropathy, IgA vasculitis, or Kawasaki disease. In some embodiments, the disease associated with IgA deposition is IgA nephropathy.
[0159] Example
[0160] The following examples are put forth in order to provide those of ordinary skill in the art with a complete disclosure and description of how to make and evaluate the compositions and / or methods claimed herein, and are intended to be purely exemplary and are not intended to limit the present disclosure.
[0161] Materials and methods
[0162] Animals and housing conditions
[0163] All animal experiments were approved by the Laboratory Animal Care and Use Committee of Peking University First Hospital (No. 201994 and No. 2021114). Mice were bred and maintained under barrier conditions and used to validate IGHA1 + / - and IGHA1+ / + Expression of human IgA1 in mice. + / + First, embryo transfer was used to achieve IGHA1 + / + The mice were sterile (GF) purified and their offspring were reared under sterile isolation conditions. Fecal samples were regularly examined using microscopy and culture techniques to confirm their GF status. Second and third, similar to conventional (CV) farmed animals, specific pathogen-free (SPF) IGHA1 + / + Mice were housed under barrier conditions or transferred to non-barrier conditions at 4 weeks of age. At 16 weeks of age, mice were euthanized and their kidneys were collected for histological examination after embedding in optimal cutting temperature compound or fixation in 10% formalin. In addition, 2-month-old IGHA1 mice housed under barrier conditions were given + / + Mice were injected intraperitoneally with 0.5 μg / g LCWE emulsified with 2 μg / g CFA or PBS three times a week for the first 2 weeks and once a week for the next 2 weeks. The observation period was extended until the mice reached 8 months of age.
[0164] Urine, terminal serum, spleen (SP), small intestine (SI), inguinal lymph nodes (ILN), mesenteric lymph nodes (MLN), Peyer's patches (PP), femur, and small intestinal mucus diluted in 3 mL PBS were collected for further analysis.
[0165] Polymerase chain reaction (PCR) and real-time quantitative (RT-qPCR)
[0166] The IGHA1 gene was identified from the tail or ear clip DNA of mice using the Mouse Direct PCR Kit (B40015, Bimake). RNA was extracted from mouse tissues based on TRIzol (15596026, Invitrogen) or RNAsimple Total RNA Extraction Kit (DP419, TIANGEN) and then purified by GoScript TM Reverse transcription (A2801, Promega) was used to reverse transcribe RNA into cDNA. cDNA and primers were combined with PowerUp TM SYBR TM Green Master Mix (A25742, Invitrogen) was used to RT-qPCR analysis was performed on a 480 instrument (Roche). GAPDH was used as an internal reference gene. The primers are listed in Table 1 below.
[0167] Table 1. RT-qPCR primers
[0168]
[0169] Serum enzyme-linked immunosorbent assay (ELISA) and Western blot
[0170] Serum mouse IgA, IgG, IgM, human IgA1, human IgA1-mouse IgG complex and polymer IgA (pIgA) complex levels binding to CD89 were determined by ELISA. The plate was coated overnight with goat F(ab')2 anti-mouse Ig (1012-01, SouthernBiotech), goat anti-human IgA F(ab')2 fragment (109-006-011, JacksonImmuno) or recombinant human CD89 protein (10414-H08H, SinoBiological). After blocking for 2 hours with phosphate buffered saline (PBST) with 0.1% Tween containing 1% bovine serum albumin (BSA) at room temperature (RT), the diluted serum and standards were added to the plate for 1 hour RT incubation. Then, horseradish peroxidase (HRP)-conjugated goat anti-mouse IgA, IgG, and IgM antibodies (1040-05, 1030-05, and 1020-05, SouthernBiotech), HRP-conjugated mouse anti-human IgA1 (9130-05, SouthernBiotech), HRP-conjugated goat anti-human IgA α chain (ab98558, Abcam), or HRP-conjugated goat anti-mouse IgG (1030-05, SouthernBiotech) were used to detect mouse IgA, IgG, IgM, and human IgA1, respectively. And to detect LCWE-specific hIgA1 and Gd-IgA1, plates were coated with 2.5 μg / mL LCWE and detected using HRP-conjugated mouse anti-human IgA1 (9130-05, SouthernBiotech), rat monoclonal anti-human Gd-IgA1 antibodies (10777, Immuno-Biological Laboratories) plus HRP-conjugated polyclonal rabbit anti-rat IgG (RS030226, Immunoway Biotechnology Company).
[0171] All the above ELISA tests were detected by tetramethylbenzidine liquid substrate system. Optical density was measured at 450 nm with wavelength correction at 570 nm. Serum galactose-deficient IgA1 (Gd-IgA1) levels were measured using the Gd-IgA1 assay kit (27600, Immunobiology Laboratories) according to the manufacturer's protocol.
[0172] Serum (0.02 μl / sample) was loaded onto a gradient SDS-PAGE (8012011, BioSci, Shenzhen, Guangdong, China) with a non-reducing loading buffer and electrophoresed at 150 V for 2 h; subsequently, they were transferred to a 0.45 μm PVDF membrane. For N-acetylgalactosamine residue (GalNAc) detection, 2 μg of FPLC-purified hIgA was desialylated as a sample by neuraminidase (GK80040, Agilent). After blocking with 5% skim milk, the membrane was incubated with HRP-conjugated goat anti-mouse IgA (1040-05, SouthernBiotech) or HRP-conjugated goat anti-human IgA α chain (ab98558, Abcam) at room temperature for 1 h for IgA detection. The membrane was detected by enhanced chemiluminescence.
[0173] Urinalysis
[0174] Urinary albumin was determined by ELISA. Plates were coated overnight with goat anti-mouse albumin (A90-134A, Bethyl Laboratories). After blocking with PBST containing 1% BSA for 2 hours at RT, diluted urine and standards were added to the plates for 1 hour RT incubation. Then, horseradish peroxidase (HRP)-conjugated anti-mouse albumin (A90-134P, Bethyl Laboratories) was used as the detection antibody. Optical density was measured as described above. Urinary creatinine levels were measured using a creatinine assay kit (DICT-500; BioAssay Systems, Hayward, CA, USA). The urine albumin / creatinine ratio (ACR, mg / g) was used to define renal function.
[0175] Flow cytometry assay
[0176] SP, PP, MLN and ILN were ground and the bone marrow (BM) was rinsed to single cells with PBS containing 2% fetal bovine serum (FBS). Then, the suspension was filtered through a 100 μm cell strainer. The red blood cells of spleen, bone marrow and whole blood were lysed by RBC lysis buffer (420301, Biolegend), and then the cells were washed in PBS containing 2% FBS. The small intestine was opened longitudinally, cut into small pieces, and washed in RPMI at 200 rpm for 30 minutes. Subsequently, the washed tissue was digested for 35 minutes in 20 ml of RPMI containing collagenase IV (V900893, Sigma), dispase II (04942078001M, Roche) and deoxyribonuclease I (SLBF7798V, Sigma) at 37 ° C. Then, the digested tissue was filtered through a 100 μm cell strainer and washed at least 2 times with PBS containing 2% FBS. Lymphocytes from digested intestinal tissue were isolated by gradient centrifugation using Histopaque-1083 (10831, Sigma).
[0177] Single cell suspensions were blocked with TruStain FcX (101320, Bio-Bio) and stained with APC / Cy7-conjugated B220 (RA3-6B2, Bio-Bio), FITC-conjugated anti-mouse IgA (1040-30, SouthernBiotech) and AF647-conjugated anti-human IgA1 (9130-31, SouthernBiotech). After washing three times, cells were resuspended in PBS containing 2% FBS for data collection by flow cytometry (Verse, BD). + In the cell gate, the percentage of mouse IgA or human IgA1 expression was analyzed.
[0178] LCWE preparation
[0179] Cell wall extracts of Lactobacillus casei (ATCC 11578) were obtained as described previously (Wan F, Wang H, Wang M et al., Journal of Pathology (J Pathol) 2022; 257 (3): 262-273). In brief, bacteria were harvested during the exponential growth phase of growth in MRS broth (BD). The bacteria were incubated overnight with 4% sodium dodecyl sulfate (SDS). The cell wall fragments were washed at least 8 times to remove residual SDS. The treated cell wall fragments were sonicated for 2 hours by cooling in a dry ice / ethanol bath. After sonication, the cell wall fragments were centrifuged at 38000 rpm for 1 hour at 4 ° C, and the supernatant was harvested. As described previously, the total rhamnose content of the cell wall was determined by colorimetric phenol-sulfuric acid extraction technique (Lehman TJ, Walker SM, Mahnovski V et al., Arthritis Rheum 1985; 28: 652-659). LCWE used in the IgA renal deposition murine model was emulsified with CFA as previously published (Wan F, Wang H, Wang M et al., J Pathol. 2022; 257: 262-273).
[0180] Tissue fixation, staining, and histopathology
[0181] Fresh kidney tissue was embedded in the optimal cutting temperature compound and frozen at 2 μm. The frozen sections were stained overnight with the following antibodies: Dylight 488-conjugated anti-human IgA (ab98553, Abcam), AF488-conjugated anti-mouse IgA (1040-30, SouthernBiotech), rat anti-mouse CD31 (553370, BD Pharmingen) plus AlexaFluor 555-conjugated anti-rat IgG (ab150166, Abcam) and rabbit anti-C3 / C3b antibody (ab200999, Abcam) plus cy3-conjugated anti-rabbit IgG (A0516, Beyotime Biotechnology). After sealing with DAPIFluoromount-G (0100-20, SouthernBiotech), the sections were imaged with a confocal microscope (LSM780, Zeiss).
[0182] Kidneys, small intestines and spleens were collected, fixed in 10% formalin solution, and embedded in paraffin blocks. All sections used for histopathology and immunohistochemistry were 2.5 μm thick. Kidneys were stained with hematoxylin and eosin or periodic acid-Schiff or Masson according to standard protocols. After antigen retrieval, the intestines and spleens with Peyer's patches were stained with HRP-conjugated anti-human IgA or HRP-conjugated anti-mouse IgA. After standard operation of the DAB color development system, nuclear counterstaining was performed with hematoxylin and the sections were sealed with neutral gum (balsam). For small intestine and kidney Gd-IgA1 staining, antigen retrieval was performed on dewaxed paraffin sections using 0.05% bacterial protease subtilisin A (P5380, Sigma-Aldrich) at room temperature for 30 minutes. Nonspecific binding was blocked with phosphate-buffered saline blocking solution containing 3% bovine serum albumin. The sections were incubated at 37°C for 1 hour with rat monoclonal anti-human Gd-IgA1 antibody (10777, Immunobiology Laboratories) and then incubated at 37°C for 30 minutes with Alexa Fluor 555-conjugated goat anti-rat IgG (ab150166, Abcam). They were also stained with Dylight 488-conjugated anti-human IgA (ab98553, Abcam) and DAPI Fluoromount-G (0100-20, SouthernBiotech) and then imaged with a confocal microscope (LSM780, Zeiss).
[0183] Immunofluorescence semiquantification of the kidney was assessed by the fluorescence intensity in the mesangial area, and the mean fluorescence intensity of the small intestine was assessed by the ratio of the positive integrated density to the villus area.
[0184] Electron microscopy
[0185] The kidney tissue of the treated mice was cut into small pieces (approximately 1 mm 3 ), fixed in phosphate buffered saline containing 2.5% glutaraldehyde, postfixed in 1% osmium tetroxide, and embedded in Epon 812 resin. Ultrathin sections were stained with uranyl acetate and lead citrate and examined using a transmission electron microscope (JEM-1230; JEOL, Tokyo, Japan).
[0186] B cell receptor repertoire sequencing (BCR-seq)
[0187] Approximately 1 cm of terminal ileum tissue with PP was washed three times in PBS and then stored in RNA (AM7020, Invitrogen). RNA extraction, library preparation, and data analysis for high-throughput sequencing were performed by Seqhealth Technology Co., Ltd. (Wuhan, China). Total RNA was extracted from the samples using TRIzol (15596018, Invitrogen) and DNA digested by deoxyribonuclease I (EN0521, Thermo Scientific). The RNA was analyzed by using Nanodrop TM One C RNA quality was determined by checking A260 / A280 using a spectrophotometer (ND-ONEC-W, Thermo Fisher Scientific). RNA integrity was confirmed by 1.5% agarose gel electrophoresis. TM 3 Fluorometer (Q33216, Invitrogen) using Qubit TM Qualified RNA was quantified using RNA HS Assay Kit (Q32855, Invitrogen).
[0188] Follow the manufacturer's instructions for use 150KC-Digital TM Stranded BCR-seq Library Prep Kit (DT0815-02, Kangce Technology Co., Ltd.) was used to prepare the BCR sequencing library using approximately 2 μg of total RNA from each sample. The kit eliminates the duplication bias in the PCR and sequencing steps by labeling the pre-amplified cDNA molecules with a unique molecular identifier (UMI) of 8 random bases. The library products corresponding to 250-500 bp were enriched, quantified, and finally analyzed in NovaSeq Sequencing. The raw sequencing data were first filtered by SOAPnuke (version 1.6.0), and then the clean reads were first clustered according to the UMI sequence, where reads with the same UMI sequence were grouped into the same cluster. The deduplicated consensus sequence was used for BCR-seq analysis. They were mapped to the international ImMunoGeneTics (IMGT) database using MiXCR software (version 3.0.3) to obtain V, D and J segment rearrangements and CDR3 sequences. P ≤ 0.05 or fold change > 2 was used to screen genes with significant differential expression. The diversity of BCR is determined by the diversity of the complementarity determining region (CDR). When composed of the same VDJ genes, the CDR3 sequence with the greatest change in the functional epitope of the antibody is called the same clone, and then Shannon's sentropy and Simpson's index are introduced to verify the diversity of BCR by the number of non-repetitive clones.
[0189] Shannon Entropy:
[0190] Simpson Index:
[0191] Quantification of O-glycopeptides in the IgA1 Hinge Region (HR) using LC-MS analysis
[0192] The final serum was diluted to 1 ml with phosphate-based saline (PBS) solution for hIgA1 purification. In the FPLC system, the IgA1 fraction was purified using a HiTrapNHS-activated HP affinity chromatography column (17-0716-01, Cytiva) coupled to a F(ab')2 fragment of a goat anti-human IgA antibody (109-006-011, JacksonImmuno). The column was washed with PBS (pH = 7.3) and the fraction was eluted with glycine (pH = 2.7). The eluted liquid was immediately neutralized with tris buffer (pH = 9.0), then pooled and passed through a 30 kDa regenerated cellulose membrane (UFC8030, Ultra-4, Millipore) ultrafiltration concentration.
[0193] Purified serum hIgA1 was loaded onto a gradient SDS-PAGE (8012011, BioSci, Shenzhen, Guangdong, China) with non-reducing loading buffer and electrophoresed for 1.5-2 h at 150 V. The gel was then stained with Coomassie protein stain (ab119211, Abcam), and the gel containing monomeric and dimeric hIgA1 was cut for O-glycosylation analysis.
[0194] The strips were cut into smaller pieces (1 mm x 1 mm) and washed with 50 mM ammonium bicarbonate at 37°C. The gel pieces were shrunk three times in 100% acetonitrile (ACN) and rehydrated in a small volume (10 μL) of 10 mM DTT, 50 mM AmBic, 55 mM iodoacetamide, or 50 mM AmBic, respectively. The small volume of solvent was then digested with trypsin at 37°C for 18 hours, followed by PNGase F treatment at 37°C for 4 hours. The glycosylated peptides were further enriched by a commercial HILIC column, dried, and reconstituted in 10 μL of 0.1% formic acid before analysis.
[0195] The peptides were first purified by Thermo Scientific EASY-nLC TM Separation was performed using a 1200 nano LC system (Thermo Fisher, San Jose) in trap-elute mode and then discharged into a Thermo Scientific Orbitrap Eclipse mass spectrometer (Thermo Fisher Scientific, San Jose) provided with a FAIMS Pro (Thermo Fisher Scientific, San Jose). Solvent A was water containing 0.1% formic acid, while solvent B was 80% ACN containing 0.1% formic acid. The sample was then separated on a trap column (Thermo Scientific Acclaim PepMap 100C18, 75 μm*2 cm, 3 μm, After loading for 3 min at a flow rate of 10 μl / min, all peptides were loaded onto an analytical column (Thermo Scientific Acclaim PepMap RSLC, 75 μm*25 cm, 1.9 μm, ) was further eluted at a flow rate of 250 nL / min. It was then washed for 14 minutes.
[0196] Full scan mass spectra were recorded in positive ion mode at a resolution of 60,000 (at 200 m / z) over a scan range of 350 to 2000 m / z. The AGC target and maximum injection time were set to 4e5 and 50 milliseconds. The dd-MS2 scan used the highest setting of 1 second, with a 30 second dynamic exclusion. Data were collected using FAMIS Pro at -45V and -65V. EThcD spectra were obtained using calibrated charge-dependent ETD parameters and 27% NCE HCD supplementary activation, with a resolution of 30,000 (at 200 m / z), an AGC target of 4e5, and a maximum injection time of 400 milliseconds.
[0197] Using ByonicTM (Version 3.8.13) and Byologic R Glycopeptide fragment data were extracted from the raw files using Protein Metrics software (version 3.8-11-x64; Protein Metrics Inc.), with mass tolerances for precursor and fragment ions set to ±10 and ±20 ppm, respectively. The Protein Metrics 78 O-linked glycan library was designated as O-glycan modification to analyze intact O-glycopeptides containing the HR peptide HYTNPSQDVTVPCPVPSTPPTPSPSTPPTPSPSCCHPR and O-glycans. A false discovery rate (FDR) of 1% was applied. The total area under the curve (AUC) in the extracted ion chromatogram (XIC) of the O-glycopeptide of interest was recorded. Each glycopeptide content was described by the ratio of AUC to the total glycopeptide content. The average HR O-glycan composition for each sample was then calculated.
[0198] Statistical analysis
[0199] Continuous normally distributed variables were expressed as mean ± standard deviation (SD). Non-normally distributed variables were expressed as median and interquartile spacing (IQR). T-test or analysis of variance (ANOVA) with least significant difference (LSD) post hoc multiple comparisons were used to compare the differences between two or more groups of normally distributed data, supplemented by linear trend tests.
[0200] IBM SPSS Statistics 26 software (SPSS Company, Chicago, Illinois, USA) and GraphPad Prism 9 software (GraphPad Software, San Diego, California) were used for all statistical methods and graphs. In a two-sided test, P < 0.05 was considered statistically significant.
[0201] Example 1. IGHA1 + / + Generation of mice
[0202] In this study, the inventors constructed a knock-in human immunoglobulin heavy chain constant region α1 (IGHA1 + / + ) mice and investigated the effects of different levels of pathogen exposure on hIgA1 expression and glycosylation. + / +The mice were generated by GemPharmatech Co. Ltd Company (Nanjing, China), and the targeting strategy was as follows Figure 1A In short, IGHA1 + / + The mice were generated using the CRISPR / Cas9 system (Cong L, Ran FA, Cox D et al., Science (New York, NY) 2013; 339(6121): 819-823) using Cas9 mRNA, sgRNA (the sequences of sgRNA are shown in Table 2 below) and donors (which were co-injected into C57BL / 6J zygotes using a microinjection method). In other words, the human IGHA1 genomic fragment (whose nucleic acid sequence is shown in SEQ ID NO: 33) replaced the mouse Igha locus. The amino acid sequence of the human IgA1 heavy chain constant region expressed by the humanized mice is shown in SEQ ID NO: 34. Subsequently, the embryos were implanted into pseudo-pregnant females to generate C57BL / 6JF0 mice. The mice were screened by PCR analysis using specific primers (primer sequences are shown in Table 3 below). This assay also determined the IGHA1 genotype and confirmed the transmission of the humanized IGHA1 allele through the germline. The F0 mice were then backcrossed to C57BL / 6J mice for two generations to obtain homozygosity for replacement of the endogenous mouse Igha gene with the human IGHA1 gene.
[0203] Table 2. gRNA sequences
[0204]
[0205]
[0206] Table 3. Genotyping primers
[0207]
[0208] Representative WT, IGHA1 + / - and IGHA1 + / + PCR analysis of mouse tail DNA confirmed that the mouse Igha gene was successfully replaced by the human IGHA1 gene ( Figure 6 A) The expression of hIgA1 and mouse IgA mRNA in leukocytes of each group showed that human IgA1 can be expressed in IGHA1 + / - and IGHA1 + / + Correct translation in mice ( Figure 6 B) IGHA1 + / + Circulating levels of human IgA1 protein in mice were comparable to levels of mouse IgA protein in WT controls ( Figure 6C) As expected, in IGHA1 + / + Mouse IgA was not detected in mice. Western blot analysis of serum samples from each group confirmed that chimeric IgA1 was expressed as a complete immunoglobulin ( Figure 1B ).
[0209] Most IgA is secreted by IgA plasma cells in mucosa-associated lymphoid tissues. To evaluate the normal expression of the human IGHA1 gene in immune and mucosal organs, we performed a double-blind analysis of WT, IGHA1 + / - and IGHA1 + / + The expression of mouse IgA and human IgA1 in the spleen ( Figure 6 D) and small intestine ( Figure 6 E) mRNA expression in IGHA1 + / + The absence of mouse IgA in mouse blood cells is consistent with the absence of mouse IgA in IGHA1 + / - and IGHA1 + / + Normal production of chimeric human IgA1 was observed in mice. Flow cytometric analysis of multiple organs (expressed as B220+ cells) showed that the human IGHA1 gene was expressed in IGHA1 + / - and IGHA1 + / + It is expressed in the spleen, small intestine, bone marrow, and lymph nodes of mice but not in WT mice ( Figure 6 FI). These results indicate that IGHA1 + / - and IGHA1 + / + The IgA expression system of the mice matched that of WT mice.
[0210] Immunohistochemical analysis of tissues presenting mouse IgA and human IgA revealed that IGHA1 + / - and IGHA1 + / + The pattern of antibody secreting cell localization in the lymphoid and mucosal tissues of mice is similar. Plasma cells are located around the rare Peyer's patches ( Figure 1C ) and intestinal lamina propria and intestinal crypts ( Figure 1D ). Overall, the human IGHA1 gene is fully expressed, thus replacing IGHA1 + / + Mouse IgA in mice.
[0211] In order to confirm that IGHA1 + / +The ability of mice to produce a variety of immunoglobulins through variable, diversity and joining gene (VDJ) rearrangement, somatic hypermutation (SHM) and class switch recombination (CSR), the inventors sequenced the B cell receptor (BCR) of the terminal ileum tissue using Peyer's patches. Using specific primers to amplify immunoglobulin subtypes (hIgA1, IgA, IgG, IgM, IgD, IgE), the inventors found that IGHA1 + / + Mice showed similar immunoglobulin subtype composition to WT mice ( Figure 1E ).IGHA1 + / + The main subtypes in the terminal ileum tissue of mice and WT mice were hIgA1 (>90%) and IgA, respectively. The inventors defined the same VDJ gene as a clone and used Shannon entropy and Simpson index to evaluate BCR diversity, which measure the number of non-repetitive clones. The higher the value of Shannon entropy and Simpson index, the greater the diversity of BCR in the sample (Feutrill, A. and M. Roughan, "Entropy" (Basel), 2021.23 (8)). hIgA1 is in IGHA1 + / + The distribution of diversity in hIgA1 was similar to that in mouse IgA in WT mice, but the absolute number of hIgA1 clones was slightly increased. The frequency of V and J gene usage in hIgA1 was also similar to that in mouse IgA ( Figure 1F , Figure 7 A). In addition, the complementarity determining region 3 (CDR3) sequences, which exhibit the greatest diversity of functional epitopes and generally range from 8 to 20 amino acids, show a uniform normal distribution in hIgA1 and IgA ( Figure 1G ). Although compared with WT mice, IGHA1 + / + BCR clusters were increased in mice, but there was no significant deviation in the clustering analysis of immunoglobulin heavy chains (IGH), as shown in the Venn diagram, which revealed 3055 common IGH sequences ( Figure 7 B). The distribution of the top 100 IGH clusters was uniform and showed no significant differences between the two lines ( Figure 7 C) Overall, IGHA1 + / + The mice successfully underwent class switching and affinity maturation to synthesize a variety of immunoglobulin classes similar to WT mice to cope with the complexity of mucosal immunity.
[0212] Example 2. LCWE-induced IGHA1 + / + Generation and characterization of mice
[0213] Pathogen exposure promotes hIgA1 production in multiple organs
[0214] IgA is the most abundant antibody isotype produced by humans and is found primarily in mucosal areas but also in the blood ( M. and The role of IgA in the pathogenesis of IgA nephropathy. International Journal of Molecular Science (Int J Mol Sci), 2019.20(24). In the human body, IgA can exist in three main forms: monomer (mIgA), polymer (mainly dimer; pIgA, dIgA) and IgA-containing complexes. All GF, SPF and CV raised IgHA1 + / + Mice synthesize three forms of hIgA1 ( Figure 2 AB, Figure 8 A). And with increasing levels of pathogen exposure, IGHA1 + / + The levels of mIgA (about 160 kD), pIgA, and especially dIgA (about 340 kD) in mouse serum increased. Feeding conditions also altered serum Gd-IgA1 levels ( Figure 2 B) IGHA1 grown under CV conditions + / + Gd-IgA1 production was elevated in mice, suggesting that infection has an effect on Gd-IgA1 export.
[0215] To determine the source of elevated serum hIgA1, the present inventors measured the mRNA expression level of IGHA1 in lymphocytes from SP, PP, MLN and ILN ( Figure 2 C). RT-qPCR results showed that IGHA1 mRNA expression increased in GF, SPF, and CV-reared mice in both systemic and mucosal sites producing hIgA1 in the order of exposure. Interestingly, the inventors found that SPF-reared mice had IGHA1 expression comparable to GF in systemic sites such as SP and ILN, while expression levels were comparable to CV in mucosal sites such as PP and MLN. Perhaps this is because IGHA1 is expressed in SPF-reared mice at a higher level than in CV-reared mice. + / + The mice established commensal bacteria at mucosal sites, but did not have sufficient pathogens to stimulate significant systemic hIgA1 production.
[0216] In humans and mice, nearly 80% of the total plasma cells in the body are located in the intestinal mucosa, where they secrete dimeric IgA (Tezuka, H. and T. Ohteki, Regulation of IgA Production by Intestinal Dendritic Cells and Related Cells. Front Immunol, 2019.10: p.1891). hIgA1 was rarely detected in the SI lamina propria of GF mice. + The present inventors have recognized that when IGHA1 is colonized with commensal bacteria + / + In mice, SI hIgA + The mean fluorescence intensity (MFI) of plasma cells increased significantly ( Figure 2 DE). These results suggest that the increase in serum hIgA1 originates from multiple immune tissues, and both systemic and mucosal sites are involved in this process.
[0217] Increased levels of serum Gd-IgA1 and hIgA1-containing complexes in IGHA1+ / + mice induced by LCWE antigen
[0218] LCWE used in the IgA renal deposition mouse model was emulsified with complete Freund's adjuvant (CFA) as previously published (Wan F, Wang H, Wang M et al., J Pathol 2022; 257: 262-273). + / + Mice were injected intraperitoneally with LCWE (emulsified with CFA) or PBS eight times and observed until they reached 8 months of age ( Figure 3 A, Fig. 9A). Gd-IgA1 has been identified as the initial trigger in the pathogenesis of IgA nephropathy (Wyatt, RJ and BA Julian, IgA nephropathy. N Engl J Med, 2013. 368(25): 2402-14; Lai, KN et al., IgA nephropathy. Nat Rev Dis Primers, 2016. 2: 16001; Novak, J. et al., Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy. Nephropathy). Seminars in Nephrology, 2018. 38(5): 461-476), and it is well known that circulating immune complexes containing IgA are pathogenic and are the most common form of renal deposition (Zhang, X. et al., Poly-IgA Complexes and Disease Severity in IgA Nephropathy. Clin J Am Soc Nephrol, 2021. 16(11): 1652-1664; He, JW et al., Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies. therapies). Theranostics, 2020.10(25): pp. 11462-11478). After LCWE antigen stimulation, IGHA1 + / + Mice export LCWE-specific hIgA1 and Gd-IgA1 ( Figure 3 B) The absolute value of serum Gd-IgA1 and its relative ratio to hIgA1 in LCWE-induced IgHA1 + / + (also referred to in this application as "IGHA + / + -LCWE”) mice ( Figure 3 CD). Moreover, hIgA1-mouse IgG complexes and CD89-bound pIgA complexes developed to higher levels after stimulation even at 8 months of age ( Figure 3 E). Serum IgM increases with age, and IgG peaks immediately after stimulation ( Fig. 9 B).
[0219] Purification of PBS- and LCWE-induced IGHA1 + / + Mouse serum hIgA1, and anti-hIgA1 antibody was used to stain and verify the hIgA1 protein in the gel ( Figure 3 F). The hIgA1 gel band was then cut and sent to LC-MS analysis of hIgA1 HR O-glycopeptides ( Fig.10 ). Compared with the PBS group, LCWE-induced IGHA1 + / + The Gal / GalNAc ratio in mouse IgA1 HR decreased, while the number of GalNAc residues remained unchanged ( Figure 3 GH).
[0220] In general, under strong mucosal stimulation, both Gd-IgA1 and hIgA1 immune complexes increased continuously, which simulated the first to third hits of the 'multiple hits' hypothesis.
[0221] TD and TI pathways are responsible for enhancing mucosal-derived Gd-IgA1
[0222] The terminal ileum is where PP is concentrated and serves as the major site for antigen sampling and immune induction in the gut-associated lymphoid tissue (GALT) 50. + / + The concentrations of hIgA1 and Gd-IgA1 in the small intestinal mucus of mice were high ( Figure 4 A) To investigate the enhancement of Gd-IgA1 in the SI lamina propria + The process of plasma cells Figure 4 B), analyzed the mRNA levels in the terminal ileum. Naive B cells that undergo class switching recombination in the intestine to produce IgA1 are regulated by T cell-dependent (TD) and T cell-independent (TI) immune responses (Tezuka, H. and T. Ohteki, Regulation of IgA production by intestinal dendritic cells and related cells. Frontiers in Immunology, 2019.10: p.1891). TGFβ is affected by both TD and TI pathways, and the inventors observed a thousand-fold increase in transcription in the LCWE-induced group compared to the other three groups ( Figure 4E). And through the TI pathway, IgA1 class switching occurs directly as a response to BAFF and APRIL secreted by DCs activated by Toll-like receptor ligands in the PP and lamina propria (Barratt, J. et al., Why Target the Gut to Treat IgANephropathy? Kidney International Reports, 2020.5(10): pp. 1620-1624; Coppo, R., The Gut-Renal Connection in IgA Nephropathy. Seminars in Kidney Disease, 2018.38(5): pp. 504-512). Under LCWE stimulation, BAFF and APRIL mRNA levels increased in terminal ileum tissue ( Figure 4 CD). Transcription of inducible nitric oxide (NO) synthase (iNOS) was also increased ( Figure 4 F), which is expressed in DCs and macrophages and mediates the production of a large amount of NO, thereby inducing TGFβ receptors on B cells in the TD pathway and inducing BAFF and APRIL expression on DCs in the TI pathway (Tezuka, H. and T. Ohteki, Regulation of IgA production by intestinal dendritic cells and related cells. Frontiers in Immunology, 2019.10: p.1891). In other words, the transcription levels of inflammatory cytokines in both the TD and TI pathways are increased, thereby increasing the expression of pathogen-stimulated IGHA1 + / + The mice developed more Gd-IgA1-secreting plasma cells in the intestine.
[0223] Gd-IgA1 triggers severe complement activation and pathological damage in the kidney
[0224] Consistent with the increasing levels of serum hIgA1 and hIgA1-containing complexes, the present inventors observed that hIgA1, especially Gd-IgA1, was significantly increased in LCWE-induced IGHA1 + / + Deposition in the mesangial region of mice, which showed continuous and stable mesangial deposition of human IgA1 (positivity: 100%) and co-deposition of C3 (positivity: 80%) until 8 months of age ( Figure 5 A) Compared with the PBS group, LCWE-induced IGHA1 + / + Mice suppressed the increase in semi-quantitative scores of C3 and hIgA1 ( Figure 5 BC). Histology showed mesangial expansion, hypercellularity, and marked increase in tubulointerstitial fibrosis. Electron microscopy showed that LCWE-induced IGHA1 + / + Typical mesangial electron-dense deposits in mice ( Figure 5D). Unlike the Kawasaki disease mouse model (Noval Rivas, M. et al., Intestinal Permeability and IgA Provoke Immune Vasculitis Linked to Cardiovascular Inflammation. Immunity, 2019.51(3): 508-521.e6), LCWE-induced IGHA1 + / + The mice had no cardiovascular or aortic inflammation ( Fig.11 A). Compared with the earlier reported LCWE-induced wild-type mice (C3 positive rate: 30%) (Wan, F. et al., Sustained release of Lactobacillus casei cell wall extractcan induce a continuous and stable IgA deposition model. Journal of Pathology, 2022.257(3): pp. 262-273), LCWE-induced IGHA1 + / + Mice had more severe complement C3 activation, mesangial expansion, and endocapillary hypercellularity (see Table 4 below). However, there were no significant differences in clinical indicators such as serum creatinine, urea nitrogen, or urine albumin-creatinine ratio after stimulation ( Fig.11 B).
[0225] Table 4. PBS-induced IgHA1 according to the Oxford IgA nephropathy classification + / + Mice, LCWE-induced WT (C57BL / 6) and IGHA1 + / + Pathological characteristics of mice.
[0226] M1 E1 S1 T1 C1 IGHA1-PBS (n=12) 9(75%) 5(41.7%) 0 0 1(8.3%) WT-LCWE (n=8) 5(62.5%) 2(25%) 0 0 0 IGHA1-LCWE (n=12) 11(91.7%) 12(100%) 0 0 3(25%)
[0227] discuss
[0228] Insights from IgAN models can provide valuable information about various aspects of the pathogenesis of IgAN and aid in the development of IgAN-specific drugs (Suzuki, H. and Y. Suzuki, Murine Models of Human IgA Nephropathy. Seminars in Kidney Disease, 2018. 38(5): pp. 513-520). Mucosal polymers IgA and Gd-IgA1 are important in the pathogenesis of IgAN (Schena, FP and SNCox, Biomarkers and Precision Medicine in IgA Nephropathy. Seminars in Kidney Disease, 2018. 38(5): pp. 521-530). The novel IgAN mouse model described herein can further deepen our understanding of the disease. The inventors successfully constructed an IGHA1 expressing a chimeric hIgA1 with a complete O-glycosylated hinge region. + / + Mouse model. Upon pathogen exposure and enhanced antigenic stimulation, mucosal hypersecreted and HR hypogalactosylated hIgA1 showed significant renal deposition and a stronger effect in activating complement and initiating inflammatory injury.
[0229] IGHA1 prepared in this application + / + The mouse model successfully expressed chimeric hIgA1 with human IgA1 heavy chain constant region and mouse variable region but without mouse IgA. During the immune response, B lymphocyte progenitor cells rearrange V(D)J gene segments to produce the antigen binding region of BCR (Cooper, MD and MN Alder, The evolution of adaptive immune systems. Cell, 2006.124(4): 815-22), perform SHM and CSR to produce high-affinity antibodies with biological effector functions (Tezuka, H. and T. Ohteki, Regulation of IgA production by intestinal dendritic cells and related cells. Frontiers in Immunology, 2019.10: 1891). BCR seq makes IGHA1 + / +The immunoglobulin gene structure of mice and WT mice is the same. Compared with α1KI mice lacking mouse IgM and having mouse IgA (Duchez, S. et al., Premature replacement of mu with alpha immunoglobulin chains impairs lymphopoiesis and mucosal homing but promotes plasma cell maturation. Proceedings of the National Academy of Sciences of the United States of America, 2010.107(7): p. 3064-9), IGHA1 + / + Mice can better defend against pathogens and mimic human mucosal immunity. In humans, 75%-90% of serum IgA is monomeric, 10%-15% is in polymeric form, and 1% is bound in circulating immune complexes ( M. and The role of IgA in the pathogenesis of IgA nephropathy. International Journal of Molecular Sciences, 2019. 20(24). The third hit of the IgAN ‘multiple hit’ hypothesis is the formation of immune complexes containing Gd-IgA1, which can form self-aggregates, complexed with anti-Gd-IgA1 antibodies (IgG or IgA) or soluble CD89 (Selvaskandan, H., J. Barratt and CK Cheung, Immunological drivers of IgA nephropathy: Exploring the mucosa-kidney link. International Journal of Immunogenet, 2022. 49(1): 8-21). Compared with healthy controls, IgAN patients have significantly higher levels of poly-IgA immune complexes (Zhang, X. et al., Poly-IgA Complexes and Disease Severity in IgA Nephropathy. Clinical Journal of the American Society of Nephrology, 2021.16(11):1652-1664). Mice do not express CD89, but the inventors can use recombinant CD89 affinity probes as an ex vivo tool to measure IGHA1 + / +Poly hIgA1 levels in mouse serum. With stronger pathogen exposure, not only the levels of hIgA1-IgG complexes, but also the levels of poly hIgA1 complexes bound to CD89 increased significantly. In addition, it is reported that up to 90% of IgAN patients from different groups around the world have elevated serum Gd-IgA1 levels (Zhang, H. and J. Barratt, Is IgA nephropathy the same disease in different parts of the world? "Semin Immunopathol", 2021.43(5): pp. 707-715). The inventors verified that IGHA1 + / + The hIgA1 hinge region of mice is O-glycosylated. And under LCWE stimulation, HR qualitatively shows reduced Gal modification. In addition, serum Gd-IgA1 levels quantitatively increased fivefold compared to controls. The inventors reported an elevated Gd-IgA1 mouse model for the first time in the world.
[0230] Chimeric IgA1 in IGHA1 + / +Functions and effects in mice are related to symbiotic flora and inflammatory responses (Monteiro, RC, Role of IgA and IgA fc receptors in inflammation. J Clin Immunol, 2010. 30(1): 1-9; Wilmore, JR et al., Commensal Microbes Induce Serum IgA Responses that Protect against Polymicrobial Sepsis. Cell Host Microbe, 2018. 23(3): 302-311.e3). Emerging evidence confirms the critical role of mucosal immunity in the pathogenesis of IgAN (Gesualdo, L., V. Di Leo, and R. Coppo, The mucosal immune system and IgA nephropathy. Seminars in Immunopathology, 2021. 43(5): 657-668).Experimental results in current IgAN-like mouse models support the view that mucosal polymer IgA exposed to food and microbial antigens through the mucosa can induce IgAN-like damage in the glomeruli (McCarthy, DD et al., Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. Journal of Clinical Research (J Clin Invest), 2011.121(10):3991-4002; Kano, T. et al., Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy. Kidney International (Kidney International ... Int, 2021.100(2):364-376; Monteiro, RC and Y. Suzuki, Are there animal models of IgA nephropathy? Seminars in Immunopathology, 2021.43(5):639-648. In secondary lymphoid organs including lymph nodes, SP, PP and other MALTs (such as GALT, T and B cells) are present and interact with trapped antigens (Megha, KB and PV Mohanan, Role of immunoglobulin and antibodies in disease management. Int J Biol Macromol, 2021.169:28-38). Compared with SPF conditions, IGHA1 raised under CV conditions. + / + Expression of human IgA1 in mice was enhanced in these immune-inducing sites. + and Gd-IgA1 + Plasma cells appear in large numbers in LCWE-induced IGHA1 + / + This may reflect the involvement of germinal center (GC)-independence or shorter GCs in LCWE-induced IgA in the SI lamina propria of mice. +B cell production (Seifert, M. and R. Küppers, Human memory B cells. Leukemia, 2016. 30(12): pp. 2283-2292). The mRNA levels in the terminal ileum explain that not only the TD but also the TI pathways affect the synthesis of mucosal hIgA1. Therefore, LCWE-induced IGHA1 + / + Mice are ideally suited to study the mucosal-renal axis in IgA nephropathy.
[0231] LCWE-induced mice showed pathological features of IgA1 and C3 deposits. By observing at 8 months of age, our model presented histological lesions of IgAN-like mesangial hypercellularity, capillary hypercellularity, segmental sclerosis, interstitial inflammation, tubular atrophy, and a few mice showed crescent formation. Compared with the earlier report of LCWE-induced wild-type mice (Wan, F. et al., Sustained release of Lactobacillus casei cell wall extract can induce a continuous and stable IgA deposition model. Journal of Pathology, 2022. 257(3): pp. 262-273), due to LCWE-induced IgHA1 + / + Mice had a greater ability to activate pathological Gd-IgA1 complement and thus had more severe complement C3 activation, mesangial expansion, and capillary hypercellularity compared with WT-LCWE mice or PBS-LCWE mice.
[0232] In conclusion, the inventors have established the world's first mouse model with elevated serum Gd-IgA1. In the future, the animal model will not only be used to explore the mechanism of genetic and environmental factors affecting IgA nephropathy, but will also help explore new treatment strategies or promote the development of new drugs. Our group has used IgHA1 + / + The in vivo effects of chimeric fusion of IgA protease with Fc were explored in mice (Xie, X. et al., Chimeric Fusion between Clostridium Ramosum IgA Protease and IgG Fc Provides Long-Lasting Clearance of IgA Deposits in Mouse Models of IgA Nephropathy. Journal of the American Society of Nephrology, 2022. 33(5): 918-935). Therefore, this model has great prospects in advancing IgAN drug development and promoting clinical translation.
[0233] Example 3. Immunostimulation using different immunostimulants
[0234] At baseline, the IGHA1 + / + Mice were injected intraperitoneally with complete Freund's adjuvant (CFA, catalog # F5881) alone, once every two weeks, for a total of 6 injections, with each injection dose of 2 μg / g mouse weight. Samples were obtained from mice aged 5 to 7.5 months at multiple times.
[0235] The results showed that the levels of human IgA1, mouse IgG, mouse IgM, and human IgA1-mouse IgG complex in the serum of 5-month-old mice were significantly increased ( Fig.12 ).
[0236] Igha1 in 7.5-month-old mice by immunofluorescence + / + The positive rates of human IgA, C3, IgM and IgG measured in the frozen sections of the kidneys of mice (mice No. 6 to 14, a total of 9 mice) were 100%, 88.9%, 100% and 33.3%, respectively ( Fig.13 ).
[0237] In the PAS pathological staining of the kidney, increased matrix was found in the mesangial region of a 4-month-old mouse (mouse No. 1); increased matrix and cells, a significant increase in endothelial cells, and segmental glomerular sclerosis were found in the mesangial region of 5-month-old mice (mice Nos. 2-3). Fig.14 In addition, slight hyperplasia was found in the mesangial region of 6-month-old mice (mice Nos. 4-5), and the lesions regressed compared with those of 5-month-old mice. For 7.5-month-old mice (mice Nos. 6-14), the lesions entered the chronic phase, and proliferative lesions were found in the mesangial region of all 9 mice. For example, increased matrix and cells in the mesangial region and segmental glomerulosclerosis were found in mouse No. 6 ( Fig.15 ).
[0238] The levels of serum creatinine (SCR) and urine albumin-creatinine ratio (ACR) were determined, and no statistically significant differences were found between 5-month-old (6-shot) and 7.5-month-old mice. However, the ACR values of mice with relatively severe renal pathology phenotypes (such as mouse No. 6) were significantly higher than those of other test mice and control mice ( Fig.16 ).
[0239] In short, stimulation with CFA alone also causes the serum IgA and complex levels of IGHA1 humanized mice to increase, and the IgA deposition rate in the mesangial region of 7.5-month-old mice reaches 100%. The pathological changes of kidney can be divided into acute phase and chronic phase. During the application period (5 months old), matrix and cells increase in the mesangial region, and endothelial cells increase significantly; after stopping application (6 months old), the lesions disappear. Subsequently, the pathological changes of kidney enter the chronic phase, and matrix and cells increase in the mesangial region of 7.5-month-old mice, and segmental sclerosis of glomeruli is found. The urine albumin / creatinine ratio (ACR) of mice with relatively severe diseases increases significantly.
[0240] Other types of immunostimulants were also tested in the examples, such as saponin, aluminum hydroxide (Al(OH)3), lipopolysaccharide (LPS), Freund's incomplete adjuvant (IFA), CFA, and LCWE emulsified with CFA (LCWE-CFA). All of these immunostimulants are commercially available, such as saponin (Sigma, catalog #SAE0073), aluminum hydroxide (Thermo, catalog #77161), lipopolysaccharide (Sigma, catalog #L2630), Freund's incomplete adjuvant (Sigma, catalog #F5506), and CFA (Sigma, catalog #F5881). The administration regimen is described in Table 5 below. For each group, at baseline, 2-month-old IGHAL was administered to 100% leukocytes. + / + The corresponding test samples were injected intraperitoneally into 2-month-old IGHA1 mice raised under barrier conditions. + / + Mice were injected intraperitoneally three times per week for the first 2 weeks and then once per week for the following 2 weeks. The observation period was extended until the mice reached 8 months of age.
[0241] Table 5. Administration schedule
[0242]
[0243]
[0244] The serum human IgA levels of each group before and after stimulation were as shown in Fig.22A and Fig. 22B As shown. Fig.22A and Fig. 22B As shown in the figure, in the LCWE-CFA group, the serum human IgA level increased significantly and continuously, and also remained at a relatively high level. In the Al(OH)3, CFA and IFA groups, the serum human IgA level also increased significantly, but decreased in the later period.
[0245] The serum human IgA-mouse IgG complex levels in each group before and after stimulation were as shown in Fig.23A and Fig. 23B As shown. Fig.23A and Fig. 23B As shown, the serum human IgA-mouse IgG complex levels in each of the Al(OH)3, IFA, CFA, and LCWE-CFA groups were significantly increased, and the serum human IgA-mouse IgG complex in the LCWE-CFA group reached the highest level.
[0246] Before and after stimulation, the urine albumin-creatinine ratio (ACR) of each group was as follows Fig.24A and Fig. 24B As shown. Fig.24A and Fig. 24B As shown, there was no significant difference in urine ACR between each group.
[0247] The deposition of human IgA (hIgA) and C3 in each group was measured by immunofluorescence and PAS pathological staining of the kidneys, as well as PAS staining. Fig.25 As shown. Fig.25 As shown, the positive rate and intensity of hIgA in the LCWE-CFA group were higher than those in all other groups, and the CFA group ranked second; the positive rate and intensity of C3 deposition in the Al(OH)3 group were higher than those in all other groups, and the LCWE-CFA group ranked second. In addition, increased matrix, widened glomerular mesangial area, and significantly increased endothelial cells were observed in the Al(OH)3, CFA, and LCWE-CFA groups, and crescents were formed in some mice.
[0248] The semi-quantitative scores of the immunofluorescence images and micrographs of the mice in each group are also shown in Table 6 and Figure 26 below. As shown in Figure 26, there was no significant difference in the intensity of mouse IgM in each group ( Fig.26A ); the intensity of human IgA (hIgA) in the LCWE-CFA group was higher than that in all other groups, and the CFA group ranked second ( Fig.26B ); the intensity of C3 deposition in the Al(OH)3 group was higher than that in all other groups, and the LCWE-CFA group ranked second ( Fig.26C ).
[0249] Table 6. Pathological staining scores of kidneys of 8-month-old mice (based on IgAN MEST-C scores)
[0250]
[0251]
[0252] Example 4. Immunostimulation using different administration routes (intraperitoneal and intranasal)
[0253] At baseline, the IGHA1 + / +Mice were injected intranasally (in) or intraperitoneally (ip) with PBS or LCWE emulsified with CFA (inLCWE or ipLCWE groups) three times a week for the first two weeks and once a week for the next two weeks over a one-month administration period. Samples were obtained from 7-month-old mice.
[0254] like Fig.17 As shown, the results showed that the levels of human IgA1 and mouse IgG in the serum of 4-month-old mice in the ipLCWE group were significantly increased compared with the PBS group; for the inLCWE group, the level of human IgA1 tended to increase, but there was no significant difference compared with the PBS group. The levels of human IgA1, mouse IgG, mouse IgM, and human IgA1-mouse IgG complex in the serum of 7-month-old mice in the ipLCWE group were significantly increased. For example, the level of human IgA1 in the ipLCWE group was twice that of human IgA1 in the PBS group. However, there were no significant differences in these biomarkers between the inLCWE group and the PBS group ( Fig.17 ).
[0255] As tested by immunofluorescence in kidney cryosections of 7-month-old mice, the positive rate of human IgA1 in the inLCWE group was 75%, which was lower than the 100% positive rate in the ipLCWE group. The positive rates of C3 in the inLCWE group and the ipLCWE group were 12.5% and 40%, respectively ( Fig.18 ).
[0256] In the PAS pathological staining assay of the kidneys of 7-month-old mice, no obvious pathological changes were found in the inLCWE group, while increased matrix and cells were found in the glomerular mesangial area in the ipLCWE group ( Fig.19 ).
[0257] In summary, by comparing the inLCWE group and the ipLCWE group, the results showed that at the end of the intranasal administration period of the inLCWE group (4 months old), the serum IgA of mice increased, and the IgA deposition rate in the glomerular mesangial region of 7-month-old mice was 75%, which was lower than the 100% deposition rate in the ipLCWE group. The positive rate and intensity of IgA and C3 in the inLCWE group were also lower than those in the ipLCWE group. In addition, no pathological changes in the kidneys were found in the inLCWE group.
[0258] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications and substitutions may be made to the embodiments without departing from the principles and spirit of the present invention and modifications thereof, the scope of the present invention being defined by the appended claims and their equivalents.
Claims
1. A method for preparing a genetically modified non-human animal, the method comprising: (i) modifying the genome of a non-human animal to incorporate nucleotides comprising a heterologous gene encoding a human IgA heavy chain constant region or a fragment thereof into its endogenous Igha locus; and (ii) treating the non-human animal produced in step (i) with a formulation comprising an immunostimulant.
2. The method according to claim 1, wherein step (i) comprises introducing nucleotides containing the heterologous gene into the pluripotent cells of the non-human animal, thereby obtaining non-human animal pluripotent cells containing the heterologous gene, and using the non-human animal pluripotent cells containing the heterologous gene to prepare a non-human animal.
3. The method according to any one of the preceding claims, wherein the nucleotide sequence comprising the heterologous gene is introduced into the pluripotent cells of the non-human animal by using a CRISPR / Cas system.
4. The method of any of the preceding claims, wherein the CRISPR / Cas system comprises a Cas9 protein and a guide RNA that targets a guide RNA target sequence within the endogenous Igha locus.
5. The method according to any one of the preceding claims, wherein the pluripotent cells are embryonic stem (ES) cells.
6. A method according to any one of the preceding claims, wherein a segment or the entirety of an endogenous non-human animal Igha gene at the endogenous non-human animal Igha locus has been deleted and replaced with the nucleotide sequence comprising the heterologous gene.
7. The method of any one of the preceding claims, wherein the non-human animal does not express endogenous non-human IgA heavy chain constant region.
8. A method according to any of the preceding claims, wherein the nucleotide sequence comprising the heterologous gene is operably linked to an endogenous regulatory element (e.g., a promoter, enhancer, silencer, etc.) of the non-human animal.
9. The method according to any one of the preceding claims, wherein the nucleotide sequence comprising the heterologous gene is a genomic fragment of the human IGHA1 gene.
10. The method according to any one of the preceding claims, wherein the heterologous gene comprises both human IGHA1 coding and non-coding sequences.
11. The method according to any one of the preceding claims, wherein the non-human animal produces a chimeric IgA1 whose heavy chain comprises a non-human animal variable region and a human constant region or a fragment thereof.
12. The method according to any one of the preceding claims, wherein the human IgA1 heavy chain constant region of the non-human animal comprises an O-glycosylated hinge region.
13. The method according to any one of the preceding claims, wherein the heterologous gene is a human IGHA1 gene encoding a human IgA1 heavy chain constant region or a fragment thereof.
14. The method of any one of the preceding claims, wherein the formulation comprises an immunostimulant and an antigen.
15. The method according to any one of the preceding claims, wherein the formulation consists of an immunostimulant.
16. The method according to any one of the preceding claims, wherein the immunostimulant is selected from the group consisting of aluminum adjuvants, emulsion adjuvants, biological adjuvants and saponins.
17. A method according to any one of the preceding claims, wherein The aluminum adjuvant is selected from the group consisting of aluminum hydroxide (Al(OH)3), aluminum phosphate, aluminum hydroxyphosphate and amorphous aluminum hydroxyphosphate sulfate (AAHS); optionally, The emulsion adjuvant is an oil-in-water emulsion adjuvant or a water-in-oil emulsion adjuvant; optionally The biological adjuvant is selected from the group consisting of: lipopolysaccharide or its derivatives, toll-like receptor (TLR) agonists (e.g., TLR4 ligands, TLR7 ligands, TLR8 ligands, TLR9 ligands), immunostimulatory oligonucleotides (e.g., DNA or dsRNA containing CpG), cytokines (e.g., IL-2, IL-7, IL-12, IL-15 and IL-23) or variants thereof, interferons (e.g., IFN-α or IFN-γ), colony stimulating factors (e.g., M-CSF and GM-CSF), tumor necrosis factor, endotoxin and lipids (e.g., lipid A or its analogs).
18. The method according to any one of the preceding claims, wherein the aluminum adjuvant is aluminum hydroxide; optionally, the emulsion adjuvant is selected from the group consisting of: Freund's complete adjuvant (CFA), Freund's incomplete adjuvant, MF59 and AS03; optionally, the biological adjuvant is lipopolysaccharide or a derivative thereof.
19. A method according to any one of the preceding claims, wherein the antigen comprises a source of rhamnose.
20. The method of any one of the preceding claims, wherein the rhamnose source is Lactobacillus casei cell wall extract (LCWE).
21. The method according to any one of the preceding claims, wherein in step (ii), the non-human animal produced in step (i) is treated with a formulation comprising LCWE emulsified with CFA.
22. The method according to any one of the preceding claims, wherein in step (ii), the formulation is injected intraperitoneally into the non-human animal.
23. The method of any one of the preceding claims, wherein the formulation is injected intraperitoneally into the non-human animal as a series of low doses.
24. The method of any one of the preceding claims, wherein the formulation is injected intraperitoneally into the non-human animal at a dose of less than 1 μg LCWE and / or less than 5 μL CFA per gram of the non-human animal.
25. The method of any one of the preceding claims, wherein the formulation is administered to the non-human animal for at least three months.
26. The method of any of the preceding claims, wherein the formulation is administered to the non-human animal produced in step (i) at an interval of three times per week in the first two weeks and once per week in the next two weeks for a period of one month; or the formulation is administered to the non-human animal produced in step (i) at an interval of once every two weeks for a period of three months.
27. The method of any one of the preceding claims, wherein the non-human animal is a rodent, a mammal, or a non-human primate.
28. The method of any one of the preceding claims, wherein the rodent is a mouse or a rat.
29. A non-human animal produced by a method according to any preceding claim.
30. A non-human animal comprising in its genome a genetically modified endogenous Igha locus comprising a heterologous gene encoding a human IgA heavy chain constant region or a fragment thereof, wherein the non-human animal exhibits clinical signs of a disease associated with IgA deposition (e.g., IgA nephropathy).
31. The non-human animal of any one of the preceding claims, wherein the non-human animal exhibits increased levels of galactose-deficient IgA protein.
32. The non-human animal of any one of the preceding claims, wherein the non-human animal exhibits increased levels of galactose-deficient IgA protein in serum or intestinal mucus.
33. The non-human animal of claim 1, wherein a segment or the entirety of an endogenous non-human animal Igha gene at the endogenous non-human animal Igha locus has been deleted and replaced with nucleotides comprising the heterologous gene.
34. The non-human animal of any of the preceding claims, wherein the non-human animal does not express endogenous non-human IgA heavy chain constant region.
35. A non-human animal according to any of the preceding claims, wherein the nucleotide sequence comprising the heterologous gene is operably linked to an endogenous regulatory element (e.g., a promoter, enhancer, silencer, etc.) of the non-human animal.
36. The non-human animal of any one of the preceding claims, wherein the nucleotide sequence comprising the heterologous gene is a genomic fragment of the human IGHA1 gene.
37. The non-human animal of any one of the preceding claims, wherein the heterologous gene comprises both human IGHA1 coding and non-coding sequences.
38. The non-human animal of any one of the preceding claims, wherein the non-human animal produces a chimeric IgA1 whose heavy chain comprises a non-human animal variable region and a human constant region or a fragment thereof.
39. The non-human animal of any of the preceding claims, wherein the human IgA heavy chain constant region of the non-human animal comprises an O-glycosylated hinge region.
40. The non-human animal of any one of the preceding claims, wherein the heterologous gene is a human IGHA1 gene encoding a human IgA1 heavy chain constant region or a fragment thereof.
41. A non-human animal according to any one of the preceding claims, wherein the non-human animal is a rodent, a mammal, or a non-human primate.
42. A non-human animal according to any one of the preceding claims, wherein the rodent is a mouse or a rat.
43. Use of a non-human animal according to any one of the preceding claims as an animal model for a disease associated with IgA deposition.
44. The use according to any of the preceding claims, wherein the disease associated with IgA deposition is selected from the group consisting of IgA nephropathy, dermatitis herpetiformis, Henlein-Schuh purpura (also known as IgA vasculitis), Kawasaki disease, purpuric nephritis, IgA vasculitis renal injury, IgA rheumatoid factor positive rheumatoid arthritis, IgA-mediated anti-GBM disease or IgA-mediated ANCA-associated vasculitis.
45. Use according to any one of the preceding claims, wherein the disease associated with IgA deposition is IgA nephropathy, IgA vasculitis or Kawasaki disease.
46. A method for evaluating the efficacy of a candidate drug for treating or preventing a disease associated with IgA deposition, the method comprising: Providing a non-human animal according to any one of the preceding claims; administering a drug candidate to the non-human animal; and assessing whether the candidate drug inhibits one or more symptoms of the disease compared to a non-human animal control not administered the candidate drug.
47. A method for identifying a candidate drug for treating or preventing a disease associated with IgA deposition, the method comprising: Providing a non-human animal according to any one of the preceding claims; administering a drug candidate to the non-human animal; and assessing whether the candidate drug inhibits one or more symptoms of the disease compared to a non-human animal control not administered the candidate drug.
Citation Information
Patent Citations
Construction method for IgAN animal model and application thereof
CN104049070A
Mouse model capable of expressing human IgA1 protein as well as construction method and application of mouse model
CN115197942A
